Podcasts about scientific advisory board

What does the future of pediatric cancer treatment actually look like?In this episode of Game Over: c*ncer, hosts Dana Nichols and Val Solomon sit down with Dr. Gregory Friedman pediatric oncologist, CKc-funded researcher, and chair of the Scientific Advisory Board at  Cannonball Kids' cancer Foundation (CKc), to talk about one of the most exciting areas in childhood cancer research: oncolytic viral therapy.Dr. Friedman explains how modified cold sore viruses can be used to safely target and kill pediatric brain tumor cells while also triggering the child's immune system to attack the tumor. He shares the science behind this innovative immunotherapy approach, what his clinical trials have shown so far, and why the future of pediatric brain tumor treatment may depend on combination therapies that work with the immune system rather than against it.If you're interested in pediatric cancer research, immunotherapy, brain tumor treatment, clinical trials, childhood cancer advocacy, or how nonprofit funding helps move science forward, this episode is packed with insight.In this episode, we cover:What oncolytic viral therapy is and how it works in pediatric brain tumorsWhy traditional immunotherapy has struggled in childhood brain cancersHow modified viruses may help the immune system recognize and attack cancerEarly clinical trial outcomes in children with high-grade gliomaWhy pediatric cancers need pediatric-specific treatmentsHow research moves from the lab to clinical trialsThe role of the Scientific Advisory Board at CKcWhy funding pediatric cancer clinical trials is so importantWhat the future of immunotherapy for childhood cancer may look like over the next decadeDr. Friedman also shares why he believes we may be approaching a new era in pediatric cancer treatment, one driven by smarter, more targeted, and more durable immune-based therapies.If you believe every child deserves better treatment options and a better chance at survival, this conversation matters.Learn more about Cannonball Kids' cancer Foundation and support pediatric cancer research: cannonballkidscancer.org----------------------------------Connect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

Too many diagnoses. Too many opinions. Too many tabs open. Not enough clarity. If you've ever felt overwhelmed trying to navigate Ehlers-Danlos syndromes (EDS), Hypermobility Spectrum Disorder (HSD), POTS, MCAS, chronic pain, or other complex health issues, you're not alone. In this episode of Bendy Bodies with the Hypermobility MD, Dr. Linda Bluestein is joined by physician assistant Rebecca Gluck, PA-C, who brings specialized genetics experience from working alongside Dr. Clair Francomano and serves on the Ehlers-Danlos Society's Medical and Scientific Advisory Board and Road to 2026 Research Committee. Together, they discuss how patients and families can move from information overload to a clearer, more practical plan. They explore how to evaluate online communities, AI tools, direct-to-consumer genetic testing, and conflicting medical opinions without becoming even more overwhelmed. Rebecca and Dr. Bluestein explain why diagnosis is often the beginning, not the end, of the journey, and why there is no single "EDS expert" who can solve every problem in one visit. They also walk through how to prioritize symptoms, identify the most functionally limiting issues, avoid unnecessary "whack-a-mole" interventions, and build a collaborative care team. This conversation is for anyone who has too many diagnoses, too many opinions, too many tabs open, and no clear next step. If you are trying to make sense of EDS, HSD, hypermobility, mast cell activation, POTS, chronic pain, genetic testing, AI-generated health information, or proposed procedures, this episode offers practical guidance to help you pause, sort through the noise, and move forward with more clarity. Takeaways: • Information overload is real, especially for people with EDS, HSD, POTS, MCAS, chronic pain, and complex multisystem symptoms. • More information does not always mean more clarity. The key is learning what applies to you, right now. • AI tools and direct-to-consumer genetic testing can help organize questions, but they are not diagnostic and can make uncertain findings sound more certain than they are. • A diagnosis can provide validation and shared language, but it is usually the start of building a plan, not the finish line. • Hypermobile EDS (hEDS) and HSD currently do not have a confirmatory genetic test. • No single clinician can be the expert in everything. Progress often comes from a collaborative care team and a clinician willing to listen, learn, and help prioritize. • When multiple diagnoses and procedures are on the table, focusing on the most functionally limiting symptoms can help prevent unnecessary or poorly timed interventions. • Addressing underlying contributors such as mast cell activation, dysautonomia, sleep, nutrition, pain, and deconditioning may sometimes reduce the need for more invasive steps. • The goal is not to chase every possible diagnosis at once. The goal is to identify the next best step. Go to AirDoctorPro.com and use promo code BENDY_ to get UP TO $300 off today! Want more Dr. Linda Bluestein, MD? Website: https://www.hypermobilitymd.com/ YouTube: https://www.youtube.com/@bendybodiespodcast Instagram: ⁠⁠⁠⁠https://www.instagram.com/hypermobilitymd/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://www.facebook.com/BendyBodiesPodcast⁠⁠⁠⁠ X: ⁠⁠⁠⁠https://twitter.com/BluesteinLinda⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/in/hypermobilitymd/⁠⁠⁠⁠ Newsletter: ⁠⁠⁠⁠https://hypermobilitymd.substack.com/ Shop my Amazon store ⁠⁠⁠ https://www.amazon.com/shop/hypermobilitymd Dr. Bluestein's Recommended Herbs, Supplements and Care Necessities: https://us.fullscript.com/welcome/hypermobilitymd/store-start Want to learn more about the UVA EDS Center? For Appointments and Questions: RUVAEDSCenter@uvahealth.org UVA EDS: https://www.uvahealth.com/healthy-practice/advancing-care-through-ehlers-danlos-clinic UVA EDS FAQ: https://www.uvahealth.com/support/eds/faq UVA Pediatric Integrative Medicine: https://childrens.uvahealth.com/specialties/integrative-health Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at ⁠⁠https://www.bendybodiespodcast.com/⁠⁠. YOUR bendy body is our highest priority!⁠⁠ Learn more about Human Content at ⁠⁠⁠http://www.human-content.com⁠⁠⁠ Podcast Advertising/Business Inquiries: ⁠⁠⁠sales@human-content.com⁠⁠⁠ Part of the Human Content Podcast Network FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links Learn more about your ad choices. Visit megaphone.fm/adchoices

Too many diagnoses. Too many opinions. Too many tabs open. Not enough clarity. If you've ever felt overwhelmed trying to navigate Ehlers-Danlos syndromes (EDS), Hypermobility Spectrum Disorder (HSD), POTS, MCAS, chronic pain, or other complex health issues, you're not alone. In this episode of Bendy Bodies with the Hypermobility MD, Dr. Linda Bluestein is joined by physician assistant Rebecca Gluck, PA-C, who brings specialized genetics experience from working alongside Dr. Clair Francomano and serves on the Ehlers-Danlos Society's Medical and Scientific Advisory Board and Road to 2026 Research Committee. Together, they discuss how patients and families can move from information overload to a clearer, more practical plan. They explore how to evaluate online communities, AI tools, direct-to-consumer genetic testing, and conflicting medical opinions without becoming even more overwhelmed. Rebecca and Dr. Bluestein explain why diagnosis is often the beginning, not the end, of the journey, and why there is no single "EDS expert" who can solve every problem in one visit. They also walk through how to prioritize symptoms, identify the most functionally limiting issues, avoid unnecessary "whack-a-mole" interventions, and build a collaborative care team. This conversation is for anyone who has too many diagnoses, too many opinions, too many tabs open, and no clear next step. If you are trying to make sense of EDS, HSD, hypermobility, mast cell activation, POTS, chronic pain, genetic testing, AI-generated health information, or proposed procedures, this episode offers practical guidance to help you pause, sort through the noise, and move forward with more clarity. Takeaways: • Information overload is real, especially for people with EDS, HSD, POTS, MCAS, chronic pain, and complex multisystem symptoms. • More information does not always mean more clarity. The key is learning what applies to you, right now. • AI tools and direct-to-consumer genetic testing can help organize questions, but they are not diagnostic and can make uncertain findings sound more certain than they are. • A diagnosis can provide validation and shared language, but it is usually the start of building a plan, not the finish line. • Hypermobile EDS (hEDS) and HSD currently do not have a confirmatory genetic test. • No single clinician can be the expert in everything. Progress often comes from a collaborative care team and a clinician willing to listen, learn, and help prioritize. • When multiple diagnoses and procedures are on the table, focusing on the most functionally limiting symptoms can help prevent unnecessary or poorly timed interventions. • Addressing underlying contributors such as mast cell activation, dysautonomia, sleep, nutrition, pain, and deconditioning may sometimes reduce the need for more invasive steps. • The goal is not to chase every possible diagnosis at once. The goal is to identify the next best step. Go to AirDoctorPro.com and use promo code BENDY_ to get UP TO $300 off today! Want more Dr. Linda Bluestein, MD? Website: https://www.hypermobilitymd.com/ YouTube: https://www.youtube.com/@bendybodiespodcast Instagram: ⁠⁠⁠⁠https://www.instagram.com/hypermobilitymd/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://www.facebook.com/BendyBodiesPodcast⁠⁠⁠⁠ X: ⁠⁠⁠⁠https://twitter.com/BluesteinLinda⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/in/hypermobilitymd/⁠⁠⁠⁠ Newsletter: ⁠⁠⁠⁠https://hypermobilitymd.substack.com/ Shop my Amazon store ⁠⁠⁠ https://www.amazon.com/shop/hypermobilitymd Dr. Bluestein's Recommended Herbs, Supplements and Care Necessities: https://us.fullscript.com/welcome/hypermobilitymd/store-start Want to learn more about the UVA EDS Center? For Appointments and Questions: RUVAEDSCenter@uvahealth.org UVA EDS: https://www.uvahealth.com/healthy-practice/advancing-care-through-ehlers-danlos-clinic UVA EDS FAQ: https://www.uvahealth.com/support/eds/faq UVA Pediatric Integrative Medicine: https://childrens.uvahealth.com/specialties/integrative-health Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at ⁠⁠https://www.bendybodiespodcast.com/⁠⁠. YOUR bendy body is our highest priority!⁠⁠ Learn more about Human Content at ⁠⁠⁠http://www.human-content.com⁠⁠⁠ Podcast Advertising/Business Inquiries: ⁠⁠⁠sales@human-content.com⁠⁠⁠ Part of the Human Content Podcast Network FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links Learn more about your ad choices. Visit megaphone.fm/adchoices

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) chief scientific and medical officer Robin Wolz tells Proactive's Stephen Gunnion that three internationally recognised specialists have joined the company's Scientific Advisory Board — two in Alzheimer's disease and one in Parkinson's — as the company deepens its position in neurodegenerative disease research. A new collaboration with the Paris Brain Institute will focus on next-generation MRI biomarkers for Parkinson's, while two IXICO scientists have been invited to contribute to the Michael J. Fox Foundation's MRI Advisory Committee. Wolz is direct about why the appointments matter: "Having them in our advisory board helps ensure that the biomarkers and approaches we're developing remain scientifically rigorous, clinically relevant and most importantly, aligned with the needs of drug developers." With Alzheimer's and Parkinson's drug pipelines expanding rapidly, demand for reliable imaging biomarkers to support clinical trials has never been higher. Watch the full interview to learn how IXICO is expanding its scientific ecosystem and supporting the development of next-generation treatments for neurodegenerative diseases. For more videos from Proactive, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #IXICO #RobinWolz #AlzheimersDisease #ParkinsonsDisease #Neuroscience #Biomarkers #MRI #MedicalImaging #ArtificialIntelligence #DrugDevelopment #ClinicalTrials #NeurodegenerativeDisease #Biotech #HealthcareInnovation #ParisBrainInstitute #MichaelJFoxFoundation

Science Forward, the podcast of the UN Secretary-General's Scientific Advisory Board, features world-leading scientists, and explores today's challenges, from AI and biotechnology to climate and health.In the very first episode of Science Forward, Board member Yoshua Bengio and AI policy expert Charlotte Stix unpack the growing risks of deceptive AI with hosts Julia Bhattacharjee and Adam Day, to answer the question: What happens when AI learns to lie?

OKYO Pharma's CEO Robert Dempsey joined Steve Darling from Proactive to announce the appointment of Dr. Marta Sacchetti, MD, PhD, as the newest member of the company's Scientific Advisory Board (SAB), a move designed to further strengthen the company's scientific and clinical expertise as it advances its lead ophthalmic programs. Dempsey explained that Sacchetti's addition enhances OKYO Pharma's already distinguished global network of scientific and medical advisors. Widely recognized for her expertise in neuro-inflammatory corneal diseases, Sacchetti brings deep knowledge and extensive research experience that aligns with the company's mission to address significant unmet needs in ophthalmology and ocular surface disease treatment. Sacchetti currently serves as an Associate Professor of Ophthalmology at Link University in Rome, Italy, and has built a strong reputation through her work spanning clinical practice, research, and industry collaboration. Her previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici adds another important dimension to her expertise, particularly in areas involving targeted nerve regeneration, pain signaling modulation, and advanced diagnostic approaches. Her research efforts have focused heavily on degenerative, allergic, and neuroimmune diseases affecting the cornea and ocular surface. In addition to her clinical contributions, Sacchetti has authored numerous peer-reviewed scientific publications and presented her findings at leading national and international conferences, reinforcing her standing within the global ophthalmology community. Dempsey noted that her appointment comes at an important stage for OKYO Pharma as the company advances its investigational treatment pipeline. The company's lead product candidate, Urcosimod, continues to gain attention as the first investigational therapy to receive an Investigational New Drug (IND) designation specifically for the treatment of neuropathic corneal pain. The program has also been granted Fast Track designation by the U.S. Food and Drug Administration, potentially accelerating its path through development and regulatory review. The appointment reflects OKYO Pharma's ongoing strategy of adding specialized expertise to support the development and commercialization of novel therapies aimed at addressing challenging ophthalmic conditions. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod #NeuropathicCornealPain #HealthcareInnovation #ClinicalDevelopment #NeuroInflammation #CornealDisease #Pharmaceuticals #MedTech #DrugDevelopment #MartaSacchetti

Send us Fan MailWe used to think of DNA as something we read. Now we're starting to treat it like something we write - and that changes everything about how medicine gets made.Dr. Patrick Finn, Ph.D. is President and COO of Twist Bioscience ( https://www.twistbioscience.com/ ), a company that's helping turn biology into something you can engineer, iterate, and even industrialize. Dr. Finn has spent his entire career building the infrastructure layer of modern biotech - from sequencing and sample prep at Beckman Coulter and Invitrogen, to scaling commercial platforms at Agilent Technologies and now Twist.Dr. Finn also served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers.So this isn't just a conversation about the future - it's about how the tools that make the future possible are actually built and deployed.On this episode we go beyond the buzzwords and dig into what it really means to “program biology”, and how close we actually are to designing medicines the way we design software.In addition to his role at Twist, Dr. Finn currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.#SyntheticBiology #Biotech #DrugDiscovery #AIinHealthcare #ArtificialIntelligence #DNA #Genomics #Bioengineering #ProgrammableBiology #CRISPR #GeneTherapy #Biotechnology #LifeSciences #MachineLearning #AIResearch #PharmaInnovation #Biology #SciencePodcast #FutureOfMedicine #Biodesign #SyntheticDNA #GenomeSequencing #Bioeconomy #DeepTech #HealthTechSupport the show

In this episode, Niall speaks with Dr. Michael Egnor, a professor of neurosurgery at Stony Brook University who has performed over 7,000 brain operations. He is also director of the neurosurgery residency program and has published extensively on the relationship between mind and brain. In this conversation, they explore: — Why decades of brain mapping research suggest that reason and free will cannot be produced by neural activity — Cases of patients missing large portions of their brain who function normally — What paradoxical lucidity in dementia patients reveals about consciousness — How research on patients in persistent vegetative states challenges materialist assumptions — Why evidence from neuroscience points to the existence of an immaterial mind And more. You can learn more about Dr. Egnor's work through his book, “The Immortal Mind". — Michael Egnor's practice includes patients diagnosed with Arnold Chiari deformity, hydrocephalus, cranio-synostosis, brain tumors, and spina bifida, as well as children with severe head trauma. He has an international reputation for research on hydrocephalus, and he is on the Scientific Advisory Board of the Hydrocephalus Association in the United States. --- Interview Link: — Dr. Egnor's Book: https://amzn.to/4bIAiv3

Send a textDr. David G. Harper is a returning guest on our show! Be sure to check out his first appearance on episode 319 of Boundless Body Radio!Dr. David G. Harper is a health educator and cancer researcher, and has studied the impact of diet on human health for many years. The culmination of that extensive work is the BioDiet, a ketogenic food regimen that he created in 2012. The significant weight loss and health improvements he experienced led Dr. Harper to counsel thousands of people on the BioDiet, in clinical trials and on a personal basis, with consistent, impressive results.He is the author of the bestselling book BioDiet: The Scientifically Proven, Ketogenic Way to Lose Weight and Improve Health, which has become an international best-seller, reaching as high as #18 globally for books overall on Amazon.com. Dr. Harper is an Associate Professor of Kinesiology at the University of the Fraser Valley and a Visiting Scientist at the BC Cancer Research Center, Terry Fox Laboratory.He holds a Ph.D. from the University of British Columbia and completed a post-doctoral fellowship in comparative physiology at the University of Cambridge. He was on the Scientific Advisory Board of the Canadian Clinicians for Therapeutic Nutrition and a member of the Institute for Personalized Therapeutic Nutrition. He is a great friend and a great human being!Find Dr. Harper at-https://www.biodiet.org/LK- Dr. David G. HarperFB- @Dave HarperReciprocal Meat Conference June 21-24, 2026 in Amarillo, TX!How It's Made - Canola Oil! UNBELIVABLY DISGUSTING.Check out his amazing talk at Keto Salt Lake 2022!Find Boundless Body at-myboundlessbody.comFind Boundless Body at- myboundlessbody.com Book a session with us here!

Send a textNishant Rastogi is the inaugural Managing Director of Lupus Ventures ( https://www.lupusventures.org/ ), the venture investment fund of the Lupus Research Alliance ( LRA - https://www.lupusresearch.org/ ), where he serves on the Investment Committee. In this role, he leads all aspects of the fund — from sourcing and evaluating opportunities to structuring deals and managing the portfolio — while overseeing team recruitment, business development, and coordination with the fund's Investment Committee and Scientific Advisory Board.Lupus Ventures is the world's only venture fund dedicated to systemic lupus erythematosus (SLE) and related autoimmune conditions. It aims to accelerate the development of new therapies and diagnostics that improve care and deliver meaningful impact for the millions of people living with lupus worldwide.A seasoned life sciences investor with over a decade of experience in venture capital and private equity, Mr. Rastogi has served as a Board Director and operating partner for multiple biotech and medtech companies. Prior to Lupus Ventures, he was Vice President and Head of Transactions at New Rhein Healthcare Investors, where he helped establish the firm's U.S. office, executed transactions across diverse therapeutic areas, and managed a portfolio totaling over $200 million in direct investments. His work spanned financing, clinical development, regulatory strategy, manufacturing, and commercialization. Notable investments include Corsair, Theranica, Alveus, American Injectables, Butterfly Medical, Softhale, EirCor, and Neuraptive.Earlier in his career, Mr. Rastogi was a founding associate at Broadview Ventures, a Boston-based venture capital fund focused on cardiovascular innovation, and has advised multiple disease research foundations — including Beyond Celiac and Parent Project Muscular Dystrophy — on venture fund formation and the intersection of philanthropy and private investment in advancing medicines and health equity. He began his career as an analyst at Fidelity Investments.Mr. Rastogi holds a B.A. in Economics and Mathematical Finance from Dartmouth College, an MBA from Northwestern University (Kellogg), a Medical Science Certificate from Harvard, and a Certificate in Climate Change and Health from Yale.#Lupus #AutoimmuneDisease #LupusResearch #BiotechInnovation #Immunology #HealthcareInnovation #PrecisionMedicine #WomensHealth #HealthEquity #VentureCapital #Biotechnology #SystemicLupus #LupusAwareness #MedicalBreakthrough #LifeSciencesSupport the show

In this episode, we welcome back Dr. Joe Chang, Chairman of Nu Skin's Scientific Advisory Board, for a forward-looking conversation on the future of health, longevity, and personalized wellness. Dr. Chang shares how decades of research, data science, and emerging technology are transforming the way we approach aging—from reactive care to proactive, measurable health optimization. He also introduces the new edition of his book, The Aging Myth, expanding on the science behind gene expression, longevity, and how individuals can take greater control of their long-term health. If you're curious about where wellness is headed next, this episode offers a powerful glimpse into the future.

Game Over: c*ncer really lives up to its name in this one. In this special episode, we celebrate 10 years of impact with the very first researcher Cannonball Kids' cancer Foundation (CKc) ever funded, Dr. Ted Johnson.Dr. Johnson is a professor of pediatric oncology and co-director of the Pediatric Immunotherapy Program at Augusta University, a destination program for children with brain cancer who have run out of standard options. Val Solomon and Dana Nichols sit down with him to talk about how one early CKc grant helped launch a decade of progress in pediatric brain cancer immunotherapy, from saving and studying monthly blood samples to building a powerful biological sample bank that is now changing what is possible for kids.You will hear how a “leap of faith” investment became the spark behind clinical trials that have now provided experimental immunotherapy to more than 270 children and young adults from over 30 states. Dr. Johnson explains how indoximod-based immunotherapy works, why activating a child's immune system is so rare and so important, and how small donations, bake sales, and grassroots philanthropy truly keep this work alive.The conversation also pulls back the curtain on CKc's Scientific Advisory Board, why it was built to push research out of the lab and into the clinic, and how that original vision has grown into a Zoom screen full of experts carefully reviewing targeted grants that directly impact kids and families. Dr. Johnson shares what he is seeing on the NIH Review Board, why pediatric grants are still outnumbered by adult oncology proposals, and what this means for the future of funding and innovation in childhood cancer.If you have ever wondered whether your $50 or $100 really matters, this episode is for you. You will hear exactly how early seed funding, focused clinical trial grants, and community support create a snowball effect that leads to new therapies, better outcomes, and real hope for children with brain cancer.Learn more about the grants we fund, our Scientific Advisory Board, and how to make a gift at: cannonballkidscancer.orgIf this conversation encourages you, please like this video, subscribe to the Game Over: c*ncer Podcast, and share it with someone who cares about changing the future for kids with cancer.Together, we can transform fear and fuel the next decade of breakthroughs.----------------------------------Connect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

Welcome to Episode 278 of Autism Parenting Secrets.You already know the gut is important. But what you may not know is that toxic chemicals from harmful gut microbes can play a major role in many of the symptoms linked with autism.My guest is Dr. James B. Adams, Director of the Autism/Asperger's Research Program at Arizona State University. He's published over 180 scientific papers, including more than 70 on autism. His work covers nutrition, gut health, toxins, seizures, and prenatal supplements. He also leads the Autism Nutrition Research Center and other groups focused on gut-brain science. And he's the father of an adult daughter with autism.Dr. Adams and his team have developed a new test that spots harmful gut toxins with striking accuracy. This breakthrough could change how we understand and treat autism.The secret this week is…Gut Toxins Drive AUTISM Symptoms You'll Discover:Why Gut Problems Often Begin In Infancy (3:15)How Harmful Bacteria and Yeast Create Powerful Toxins (5:40)The Surprising Link Between Toxins and Key Neurotransmitters (6:22)What The New Urine Test Reveals What Other Tests Miss (12:44)Why Addressing Constipation is a Critical Step to Lowering Toxin Levels (15:07)About Our Guest:James B. Adams, Ph.D., is the Director of the Autism/Asperger's Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it, including nutrition, oxidative stress, gut bacteria, microbiota transplant, probiotics, toxic metals, and seizures. He has extensively researched prenatal supplements to reduce pregnancy complications and infant health problems and developed the first prenatal supplement tailored for each trimester. He has published over 180 peer-reviewed articles, including over 70 on autism. Dr. Adams is the President of the Autism Nutrition Research Center, Autism Diagnostics, and Gut-Brain-Axis Therapeutics, and chairs the Scientific Advisory Board of the Neurological Health Foundation. He is also the father of an adult daughter with autism.http://www.adamsautismresearch.comReferences In This Episode:Gut Toxin Test → analutos.comGut-Brain Axis Therapeutics → gbat.comAutism Nutrition Research Center → autismnutritionresearchcenter.orgAdditional Resources:To learn more about personalized 1:1 support, go to www.elevatehowyounavigate.comTake The Quiz: What's YOUR Top Autism Parenting Blindspot?If you enjoyed this episode, share it with your friends.

In this episode of The Lebanese Physicians Podcast, Drs. Khalil Diab and MohammadAli Jardaly speak with Nadine Sabra, digital health lead at the American University of Beirut's Global Health Institute and member of the Scientific Advisory Board for the Health AI Conference. We discuss: Nadine's journey into digital health and AI The most promising applications of AI in healthcare today The ethical and regulatory challenges in integrating AI into practice How AI can shape patient care and health systems in the next decade AUB's initiatives to prepare the next generation of leaders in digital health This is a forward-looking conversation about how the Middle East and the world can harness AI responsibly to build more equitable, innovative, and resilient health systems.   #HealthAI #DigitalHealth #GlobalHealth #MedicalInnovation #FutureOfHealthcare #AUB #Lebanon #AIInMedicine #EquityInHealth #LebanesePhysiciansPodcast   This episode can be found on all podcast apps

Patrick Holford  Patrick Holford, BSc, DipION, FBANT, NTCRP, is a leading spokesman on nutrition and mental health and founder of both the Food for the Brain Foundation, VitaminC4Covid and the Institute for Optimum Nutrition, an educational charity that offers degree accredited training in nutritional therapy. Originally trained in psychology. Patrick was involved in groundbreaking research showing that multivitamins can increase children's IQ scores – the subject of a Horizon television documentary in the 1980s. He was one of the first promoters of the importance of zinc, essential fats, low-GL diets and homocysteine-lowering B vitamins and their importance in mental health and Alzheimer's prevention, working closely with David Smith, Emeritus Professor of Pharmacology at the University of Oxford. He is CEO of the charitable Food for the Brain Foundation and Director of the Alzheimer's is Preventable campaign and Chair of their Scientific Advisory Board. He is the author of several papers and 46 books, translated into over 30 languages, including The Optimum Nutrition Bible, Optimum Nutrition for the Mind, Food is Better Medicine than Drugs, the Ten Secrets of Healthy Ageing and Upgrade Your Brain, as well his latest book Alzheimer's:Prevention is the Cure. He is a retired visiting professor at the University of Teeside and is in the Orthomolecular Medicine Hall of Fame and on the Editorial Board for the Orthomolecular News Service. Patrick brings 40 years of research and experience in the field of nutrition. Link to Show Notes on Website https://fabulouslyketo.com/podcast/245 Patrick’s Top Tips Eat stuff that you can pull out of the ground or out of a tree or eggs, meat fish. Get sugar down. Take fish seriously especially oily fish. Move towards whole foods that have not been sprayed with pesticides. Patrick’s Books Alzheimer’s:Prevention is the Cure: You are the master of your brain’s future health – Patrick Holford Upgrade Your Brain: Unlock Your Life's Full Potential – Patrick Holford And many more books Resources Mentioned Cognitive Function Test Connect with Patrick Holford on social media Facebook: https://www.facebook.com/patrickholford Instagram: patrickholford.uk YouTube: https://www.youtube.com/@FabulouslyKeto Website Details: https://foodforthebrain.org https://www.patrickholford.com The Fabulously Keto Diet & Lifestyle Journal: A 12-week journal to support new habits – Jackie Fletcher If you have enjoyed listening to this episode – Leave us a review By leaving us a review on your favourite podcast platform, you help us to be found by others. Support Jackie Help Jackie make more episodes by supporting her. If you wish to support her we have various options from one off donations to becoming a Super Fabulously Keto Podcast Supporter with coaching and support. Check out this page for lots of different ways to support the podcast. https://fabulouslyketo.com/support Or You can find us on Patreon: https://www.patreon. com/FabulouslyKeto Connect with us on social media https://www.facebook.com/FabulouslyKeto https://www.instagram.com/FabulouslyKeto1 https://twitter.com/FabulouslyKeto https://www.youtube.com/@FabulouslyKeto Facebook Group: https://www.facebook.com/groups/FabulouslyKeto Music by Bob Collum Recommend a guest We would love to know if you have a favourite guest you would like us to interview. Let us know who you would like to hear of if you have a particular topic you would like us to cover. https://fabulouslyketo.com/recommend-a-guest We sometimes get a small commission on some of the links, this goes towards the costs of producing the podcast.

Dr. Lori Bestervelt is Senior Vice President of Certification Services at TruShield Certified and a member of the PCC's Scientific Advisory Board. She was previously Chief Science Officer at NSF International for 22 years, and she has over 20 years of experience in sport certification programs. Dr. Bestervelt discussed the importance of banned substance certification, the gap in the market that TruShield Certified was created to address, the kinds of products they test and certify, how the certification process works, collaborations with other stakeholders in the anti-doping community, and more.

Investing in Heart Health Innovation: A Conversation with Forbes 50 Over 50 Honoree Lisa Suennen of AHA Ventures Welcome to today's episode where we have the distinct privilege of speaking with Lisa Suennen, Managing Partner of American Heart Association Ventures, who was just featured in Forbes 50 Over 50 and we couldn't be more thrilled to congratulate her on this well-deserved recognition! This honor celebrates Lisa's extraordinary impact as a true powerhouse in healthcare innovation and venture capital. With over 35 years of experience at the intersection of healthcare, technology, and investment, Lisa brings an unparalleled perspective on how we can transform healthcare delivery and outcomes. At American Heart Association Ventures, she leads a multi-fund platform that's investing in the future of healthcare across the entire spectrum—from cutting-edge medical technologies to addressing critical social determinants of health. Her career has spanned multiple dimensions of the healthcare ecosystem: • Venture Capital Leadership: From her current role at AHA Ventures to previous General Partner positions at Manatt Ventures, Psilos Group, and GE Ventures, where she led the healthcare fund and served on the overall Investment Committee • Entrepreneurial Success: Co-founded and served as CEO of CSweetener, a healthcare leadership development company that was successfully acquired by HLTH Foundation • Strategic Advisory Roles: Chairs the Scientific Advisory Board of NASA's Translational Research Institute for Space Health and serves on the International Investment Committee of the ANDHealth Digital Health Fund • Thought Leadership: Author of the widely-read Venture Valkyrie blog, internationally recognized speaker, and faculty member at UC Berkeley's Haas School of Business • Industry Recognition: Fellow of the prestigious Aspen Institute's Health Innovators Fellowship Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Welcome to another powerful episode of the Game Over: c*ncer podcast by Cannonball Kids' cancer Foundation (CKc)!In this conversation, hosts Dana and Val sit down with Dr. Cassie Kline, attending physician and Director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia.Dr. Kline shares her journey into pediatric oncology, her personal connection to cancer research, and her role in advancing innovative treatments for children with brain and spinal cord tumors. From her early days as CKc's first Young Investigator to serving on CKc's Scientific Advisory Board, Dr. Kline's story highlights the critical impact of research funding, mentorship, and collaboration in creating real hope for families.You'll hear insights on:The challenges young investigators face and why early funding is crucialHow clinical trials and immunotherapy are changing the future of pediatric brain tumor careThe role of CKc's Scientific Advisory Board in ensuring the most innovative research is fundedDr. Kline's perspective as a woman in STEM and the importance of diversity in medicineThis episode is a must-listen for anyone passionate about pediatric cancer research, advocacy, and the fight to deliver better treatment options for kids.Tune in to hear this inspiring and informative conversation. Don't forget to subscribe, leave a review, and join the fight to make Game Over: c*ncer a reality.Connect with our Guest Dr. Cassie Kline:  https://www.chop.edu/doctors/kline-cassieConnect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes. As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living. He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. Websites: https://health-truth.com/ https://www.newyorkcitycandidadoctor.com/ https://www.newyorkcitythyroiddoctor.com/ YouTube: https://youtube.com/@health-truth3669 LinkedIn: https://www.linkedin.com/in/michael-biamonte-b8616b8/ Facebook: https://www.facebook.com/profile.php?id=100050863466219# Order Dr. Biamonte's Book, "The Health Chronicles" here: https://a.co/d/gRNovb8 Timestamps: 00:00 Trailer 00:37 Introduction 05:03 Assessing gut microbiome health 06:59 Insights on advanced stool testing 12:41 Candida's impact on nutrients 14:35 Carnivore diet for candida control 19:21 Targeted gut health protocols 20:32 Role of prebiotics in gut health 25:54 Benefits of fermentation 29:27 Unique treatment requirements 31:56 Risks of long-term anti-fungal use 36:02 Parasite-induced health mystery solved 38:09 Dysbiosis and Herxheimer reactions 42:16 Where to find Dr. Biamonte 44:31 Candida and thyroid connection Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

We love to hear from our listeners. Send us a message. On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Is your biotech startup feeling the squeeze of a tough funding environment? In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, have a candid, advice-packed discussion about how biotech founders can manage funding challenges, extend runway, and stay resilient when capital is tight. With practical examples and hard-earned insights, they explore strategies for leading lean teams, strengthening investor relationships, and building scrappy collaborations that move innovation forward—even in difficult times. In this episode, you'll learn: How to build resilience and make smart trade-offs when resources are limited. The importance of transparency, adaptability, and mission-driven decision-making. Why now may be the best time to build partnerships, strengthen investor relations, and refocus on what matters most. Get ready to lead with clarity, keep your cool, and chart a path forward—no matter what the market throws at you. Links: Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Maykr, as well as The Study, Elaine's wine bar. Check out previous episodes on Mastering Resilience and Building a Scientific Advisory Board and Board of Directors. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. And click here to apply for a startup pitch slot. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced, initially designed for aerospace purposes.  As a practitioner for over 30 years, Dr Biamonte is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology.   FREE BOOK:   Send an email to: drb@health-truth.com    request: The Candida Chronicles & 5 Phase Treatment     Contact:   Web  www.health-truth.com   Facebook - https://www.facebook.com/The-Biamonte-Center-241435772676317/   YouTube - https://www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ

SHINING WITH ADHD #195: Why ADHD Sleep Problems Happen and How You Can Help: Practical Strategies from A Sleep ExpertThe Childhood Collective4/30/2025SUMMARYIs your child dealing with ADHD sleep problems? Many children with ADHD have trouble falling asleep, staying asleep, or waking too early. The truth is, it can be incredibly difficult for the entire family. Today, we have the honor of talking with Dr. Roberto Olivardia, a leading expert on ADHD and sleep, to uncover why these challenges happen—and, more importantly, how you can help. Effortlessly combining the science of sleep with humor and creative ideas, Dr. Olivardia shares innovative sleep strategies for ADHD that can make nights (and mornings!) easier for you. MEET DR. OLIVARDIADr. Roberto Olivardia is a Clinical Psychologist, Clinical Associate at McLean Hospital and Lecturer in the Department of Psychiatry at Harvard Medical School. He is on the Scientific Advisory Board for ADDitude, as well as sits on the Professional Advisory Boards for Children and Adults with ADHD (CHADD), the Attention Deficit Disorder Association (ADDA), and is a Featured Expert for Understood. He presents at many conferences, podcasts and webinars around the country. LINKS + RESOURCESEpisode #195 TranscriptContact Dr. OlivaridaThe Childhood Collective InstagramHave a question or want to share some thoughts? Shoot us an email at hello@thechildhoodcollective.comMentioned in this episode:Shining at SchoolShining at School is a video-based course that will teach you how to help your child with ADHD go from surviving to thriving at school for elementary and middle schoolers. On your own time. At your own pace. Use the code PODCAST for 10% off!Shining at School CourseHungryrootHungryroot offers “good-for-you groceries and simple recipes.” We have loved having one less thing to worry about when it comes to raising kids. For 40% off your first box, click the link below and use CHILDHOOD40 in all caps to get the discount.HungryrootZenimalWe love the Zenimal. It's amazing for kids who are feeling anxious or need a little help calming their busy body before bed. The best part? Each meditation ends with the most beautiful message: “You're a good kid!” Use our code: TCC for a 15% off discount.Zenimal

In this special rerun episode of The Poultry Nutrition Blackbelt Podcast, we revisit our conversation with Dr. Michael Rothrock Jr., from USDA-ARS, who discusses his work in pre-harvest food safety and its impact on poultry systems. He shares insights into microbial ecology, soy-free diets, and the critical role of the microbiome in food safety and bird health. Gain valuable knowledge on how feed composition and environmental factors influence poultry production. Listen now on all major platforms!"The whole picture starts with the ecology; it influences everything, even feed additive effectiveness."Meet the guest: Dr. Michael Rothrock Jr. is a USDA Research Microbiologist with over 19 years of experience. He specializes in molecular microbial ecology and food safety microbiology. With a Ph.D. in Microbiology from Arizona State University, Dr. Rothrock is on the Scientific Advisory Board for the OECD - Cooperative Research Program.What you'll learn:(00:00) Highlight(01:34) Introduction(02:44) Pre-harvest food safety explained(04:12) Insights on pastured systems(05:07) Diets and microbiomes(07:06) Feed ingredients and pathogens(10:24) Role of microbial ecology(14:04) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Kemin* Kerry- Poultry Science Association- Barentz- Zinpro- Anitox- BASF

Today, I have the pleasure of speaking with Volker Then, an independent Senior Impact Analyst who is launching a start-up company on Comprehensive Impact Measurement together with a coalition of impact partners. From 2022 to 2024, Volker was Founding Chief Executive Officer and Member of the Executive Board of Fondazione AIS (Advancing Impact and Sustainability) in Bologna. Earlier in his career, Volker was Executive Director of the Centre for Social Investment at Heidelberg University for 15 years and also served as Director Philanthropy and Foundations at the Bertelsmann Foundation. He is a former member of the Scientific Advisory Board of the OECD's Global Action “Social and Solidarity Economy” and served on the National Advisory Board of the G7-Social Impact Investment Task Force. Impact is a big word nowadays – maybe even a buzzword – and people in our space are using it broadly and frequently. But it's not clear that everyone has a clear shared definition of the term. Volker provides his definition of “impact”, especially as it relates to enterprise families and the objectives they set for themselves with regard to fulfilling the purpose of their wealth and their family capital. One of the greatest challenges, and opportunities, in the world of impact is the measurement of the effectiveness and outcomes of impact initiatives. Volker talks about the latest thinking and work that is being done in this area, especially the thought leadership and development he has been spearheading in his prior role at Fondazione AIS and now in his current venture. Volker offers his tips and suggestions for enterprise families who are just starting or are early in their impact journey, focusing on what he recommends they do to get better educated and equipped to realize their impact ambitions. He then turns to enterprise families who are more advanced and have a developed impact framework and strategy, sharing his advice on what they can do to further the reach and consequence of their impact programs and strategies. Don't miss this enlightening conversation with one of the foremost thought leaders in the realm of impact definition and measurement.

What's the difference between a Scientific Advisory Board and a Board of Directors—and why does it matter for your startup's success? In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, break down the critical roles that Scientific Advisory Boards (SABs) and Boards of Directors (BODs) play in the biotech startup world. With candid insights, real-world stories, and practical advice, this episode gives you a front-row seat to the boardroom—and why who you put there can make or break your company. In this episode, you'll discover: The strategic differences between SABs and BODs—and how to know when to build each one. How to identify the right board members, what to avoid, and when to grow your board. Common pitfalls (like yes-men and micromanagers) and how to build a board culture rooted in trust, transparency, and mission alignment. Whether you're forming your first board or thinking about your next funding round, tune in to learn how to build boards that work for your company, not against it. Links: Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development and the School of Medicine. Check out Osage University Partners and connect with Kirsten Leute, MBA. Listen to our previous episode with Kirsten Leute on The Equalize Program. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Hi friends! I'm so excited to have Dr. Michael Biamonte on the show today and we're talking all about Candida.   - What is Candida and why do traditional treatments fail? - How do parasites contribute to Candida? - His protocol for rebalancing the body with Candida overgrowth - His tips for being Healthy in Real Life  and so.much.more. Here's more info about Dr. Biamonte: Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes. As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living. He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. You can check out his website, connect with him on Instagram, and read his book here.  Partners: The Lifewave X39 patches have been a gamechanger for my energy; the Pilot is obsessed, too! Check them out here.  Check out my new favorite red light device here, and use the code FITNESSISTA for a huge discount.  I've been using Nutrisense on and off for a couple of years now. I love being able to see how my blood sugar responds to my diet and habits, and run experiments. You can try out Nutrisense here and use GINA50 for $50 off. If any of my fellow health professional friends are looking for another way to help their clients, I highly recommend IHP. You can also use this information to heal yourself and then go one to heal others, which I think is a beautiful mission. You can absolutely join if you don't currently work in the health or fitness industry; many IHPs don't begin on this path. They're friends who are passionate to learn more about health and wellness, and want to share this information with those they love. You can do this as a passion, or start an entirely new career. You can use my referral link here and the code FITNESSISTA for up to $250 off the Integrative Health Practitioner program. I highly recommend it! You can check out my review IHP Level 1 here and my review of Level 2 here. Thank you so much for listening and for all of your support with the podcast! Please be sure to subscribe, and leave a rating or review if you enjoyed this episode. If you leave a rating, head to this page and you'll get a little “thank you” gift from me to you. 

The amount of time children and adolescents spend with a screen is absolutely stunning. Lots of people, including parents, health leaders, educators, elected leaders from both parties I might mention, and even children themselves, are highly concerned and are discussing what might be done about all this. I'm delighted to begin this series of podcasts on children and screen time. Today we're welcoming two very special guests who can talk about this topic in general, and especially about what's being done to protect children and adolescents. Several podcasts will follow this one that deal with food and nutrition in particular. Our first guest, Kris Perry, is Executive Director of Children and Screens, an organization devoted to protecting children. In the digital world by addressing media's impact on child development, communicating state-of-the-art information, and working with policymakers. Prior to joining children in Screens, Kris was senior advisor of the Governor of California and Deputy Secretary of the California Health and Human Services Agency. Our other guest, Dr. Dimitri Christakis is a professor of pediatrics at the University of Washington School of Medicine, and director of the Center for Child Health Behavior and Development at Seattle Children's. He's also editor-in-chief of JAMA Pediatrics and both Chief Scientific Officer and Chair of the Scientific Advisory Board of Children and Screens. He's also the co-editor of a new book that I'm very excited to discuss. Interview Summary Download The Handbook of Children and Screens: https://link.springer.com/book/10.1007/978-3-031-69362-5 Kris, let's start with you. Could you set the stage and give us some sense of how much time children spend in front of screens, children and adolescents, and what devices are being used and what kind of trends are you seeing? Yes, I'd be happy to. I had better news for your listeners, but as you might imagine, since the advent of the smartphone and social media, the youth digital media use has been increasing each year. Especially as children get older and have increasing demands on their time to use screens. But let's just start at the beginning of the lifespan and talk about kids under the age of two who shockingly are spending as much as two hours a day on screens. Most spend about 50 minutes, but there's a significant chunk spending up to two hours. And that rises to three or three to five hours in childhood. And eventually in adolescence, approximately eight and a half hours a day our adolescents are spending online. Also wanted to talk a little bit about middle childhood children, six to 12 years of age. 70% of them already have a social media account, and we all know social media wasn't designed for children. And there are restrictions on children under 13 using them, and yet children six to 12 most have an account already. Over half of four-year-olds have a tablet and two thirds of children have their own device by the age of eight; and 90% of teens. This probably won't be surprising, and yet we should really think about what this means; that 90% of teens are using YouTube, 60% are on TikTok and Instagram, and 55% use Snapchat. I'll stop by ending on a really alarming statistic. Oh my, there's more? There's more. I know it! I told you. I'll be the bearer of bad news so that we can talk about solutions later. But, children are checking their devices as often as 300 times per day. 300 times. 300 times per day, and we're talking about screen time right now. And we know that when you're using time to be on screens, you are not doing something else. And we know that childhood is full of challenges and skill building and mastery that requires repetition and tenacity and grit and effort. And the more children are on their screens, whether it's social media or other entertainment, they're not doing one of these other critical child development tasks. That's pretty amazing. And the fact that the older kids are spending more time on before a screen than they are in school is pretty alarming. And the younger, the really youngest kids, that's especially alarming. So, Dimitri, why should we fret about this? And I realize that fret is kind of a mild word here. Maybe all I'll panic would be better. But what are some of the major concerns? Well, I don't think panic is ever the right reaction, but the numbers Kris conveyed, you know, I think do paint a, let's say, concerning story. You know, the simple reality is that there's only so much time in a day. And if you think about it, teenagers in particular should sleep for eight to 10 hours a day at a minimum. They really should be in school six and a half, seven hours a day. And then when you add the numbers, Kris conveyed, you realize that something's giving because there isn't enough time left to spend eight and a half hours a day. The two things at a minimum that are giving are sleep. Kids are losing sleep to be on screens. And I'm sorry to say that they're losing school while they're on screens. We just published a paper that used passive sensing to see where and when children are on their screens. And found that the typical child in the United States spends an hour and a half during the school day on their device. And it's not, before any of your guests ask, on Wikipedia or Encyclopedia Britannica. It's on the usual suspects of social media, TikTok, etc. So, you know, we talk about displacement, and I think it's pretty obvious what's being displaced during school hours. Its time focused on learning if it's in the classroom, and time focused on being authentically present in real time and space if it's during recess. School hours are precious in that way, and I think it is concerning that they're spending that much time in school. And I told you the median. Of course, some kids are above that, a significant half of them are above it. And at the high end, they're spending 30 to 40% of school time on screens. Now, some schools have enacted policies. They don't typically enforce them very well. One of the things that drives me nuts, Kelly, is that as an academic, you know we love to argue amongst ourselves and hem and haw. And this issue about whether or not there's such a phenomenon as digital addiction is still being hotly debated. Honestly, the only behavioral addiction that's being seriously considered at this point is gaming disorder. The DSM-5 didn't consider gaming, considered it, but didn't include, it said it needed further study in 2013. In 2022, the WHO did include gaming disorder as an ICD-11 diagnosis. But just as further evidence how slow science is compared to technology., I mean gaming, while it's still an entity, represents a small fraction of most people's screen time. And the numbers that Kris conveyed, a small fraction of that for some on average was gaming. For some people, it's their screen use of choice, but for many, it's social media. YouTube, although I consider YouTube to be a social media, etc. And at the high end when you hear the numbers Kris conveyed in my mind that's a behavioral addiction any way you define it. Well, and if you think about things that we all agree are addictive, like nicotine and alcohol and heroin, people aren't doing it 300 times a day. So it's really pretty remarkable. And that's exactly right. One of the salient criteria for those addictions is that it's interfering with activities of daily living. Well, you can't be on a screen for nine hours a day when you're supposed to be asleep for 10 and at school for six without interfering with activities of day. The math isn't there. And things like being physically active and going out and playing. That's right. It doesn't add up. So, you don't need the DSM-5. You don't need a psychiatrist. You need a mathematician to tell you that there's too much time on this thing. Alright, so Kris, talk to us if you will, about the Children and Screens organization. I have a lot of respect for the organization and its work. Tell us how it got started and what its objectives are. Well, it's so great to be on this show with you and get to see you in your day job, Kelly. Because you've been an advisor, like Dimitri, to the institute almost since its inception, which is in 2013. As you know, our founder, Dr. Pamela Hurst-Della Pietra, really became concerned as a parent about the way digital media was impacting her children and sought out some answers. Well, what does this mean? Why is this happening? What should I do? And found out that this, of course, is 2013, this is a long time ago. There wasn't that much research yet. And it was multidisciplinary. In other words, there might be a study among neuroscientists or developmental psychologists, even ophthalmologists. But there really hadn't been, yet, a concerted effort to bring these different disciplines and the research together to try to answer some of these hard questions about the impact on kids. And lo and behold, here we are, almost 13 years since the advent of the smartphone and social media. And there is an astounding amount of research across disciplines. So, what we do at the institute is we try to translate it as fast as we can and make it actionable for parents, providers, and policy makers. And we do that through our Ask the Experts webinar series where we bring the experts themselves directly to our audience to talk about these impacts and answer questions. We also create printables, you might say, like tip sheets and Research at a Glance Digest, and newsletters and FAQs and we've upgraded our website to make it very navigable for parents of kids of all ages. I even started my own podcast this year, which has been really fun. Dimitri was my first guest, so it's great to see him here. And we have convenings. We're having our third Digital Media Developing Mind Scientific Congress this summer where the experts come together in person to discuss issues. And we really try to focus them on advancing research and supporting it, translating it, and positioning the issue as a policy priority. We'll be in Washington, DC where we know lawmakers are grappling with the impact of digital media on child development, how to make online, products safer for kids and protect their data. The Institute is in the middle of all of this, trying to facilitate more discussion, more results and more support for parents primarily. Kris, a couple of things occur to me. One is that the breadth of work you do is really very impressive because you're not only having very hands-on kind of in the real world ex advice for parents on how to navigate this world, but you have advice for and helpful resources for policy makers and for researchers and people. It's really quite an impressive breadth of work. The other thing that occurred to me is that I don't think you and I would have any podcast career at all if it hadn't been for Dimitri helping us out. So thanks Dimitri. Yeah. So, let me ask you, Dimitri, so I know that both you and Kris are committed to an evidence-based approach to making policy. Yeah. But technology advances way more quickly than scientists can evaluate it. Much less come up with policies to deal with it. And by the time research gets funded, completed, published, you're on to eight new levels of technology. So how does one handle this fundamental problem of pace? It's a really good question. I mean, I can tell you that we should at a minimum learn from the mistakes we've made in the past. And, you know, one of the most critical, frankly, that most people don't really understand is that we talk about the age at which children get social media accounts in this country. Kris pointed out that actually pre-teens routinely have social media accounts. Social media companies do very little to age gate. They're trying to do more now, but even the age at which we've accepted it is being normative is 13. Few people know where that comes from. That doesn't come from talking to pediatricians, psychologists, parents about what age is the appropriate age. It comes entirely from COPPA (Children's Online Privacy Protection Act), which basically was the original privacy act that said that before the age of 13, companies could not collect data from children. So, because these companies were interested in collecting data, they set the age at 13 so as to not have any constraints on the data they collected. Well, that's not even common sense-based policy, let alone evidence-based policy. And it's never been revisited since. It's very troubling to me. And as things move forward, I think we have to learn from those mistakes. Medicine has a maxim which is do no harm. We use that phrase a lot and I think it's a good one in this case. I think it's a particularly good one as we see the new technologies emerging around artificial intelligence. And you know, again, like any new technology, it has incredible upside. We made the mistake and we're still paying for it, about not appreciating the downsides of social network sites, and frankly, the internet in general. And I would hope we put guardrails in place now. And if you will apply the same standard we apply to other non-technology based products. You can't introduce a new pharmaceutical to anybody, let alone to children, until you show it's safe and effective. You can't bring toys to the world that are dangerous. Why do we have more safety precautions around toys than we do around websites for children? You know, a lot of it involves changing defaults, doesn't it? Because if the default is that government or somebody out there has to prove that something is harmful before it gets taken away. That changes everything then if you began at a different point where these companies have to prove that these things are safe. Correct. Or they're permitted. Then the companies would find workarounds and they would play games with that too, but at least that would help some. Well, it would help some. And at least we'd be philosophically in the right place. By the way, Kris didn't say it, so I'll say it. You know, the mission of Children and Screens, lest we sound like Luddites here, is not get kids away from technology. Take away their smartphones. We all recognize that technology is here to stay. I think all of us appreciate the incredible upside that it brings to children's lives. The mission of Children and Screens is to help children lead healthy lives in a digital world. And part of the reason she and I often talk about the concerns we have is because the pros make the case for themselves. I mean, you know, no one needs to come here and tell you how amazing it is that you could Google something or that you could get somewhere with GPS. I mean, we know it's amazing and we all rely on it. And none of us are ever talking about getting rid of that stuff. That makes good sense. It's like, you know, children benefit from the fact that they can get around with their parents in the automobile. But you want to have car seats in there to protect them. Exactly. And that's exactly right. There needs to be assurances of safety and they're none. I mean, they're really virtually none. The age getting is a joke. And even if we accept it as effective, the age set of 13 is too young, in my opinion. We started this conversation talking about these medias being addictive, I believe they're addictive. There are legitimate academics that will debate me on that, and I'm happy to join that debate. But as I said before, it's a tough argument to win when people spending upwards of 10 to 16 hours a day doing it. I don't know what you call that besides addictive. We can argue about what percentage are doing that, but nevertheless, once you accept something as addictive, for other addictive things we immediately age gate it above 18 or 21, right? Mm-hmm. We don't believe that the teenagers have the ability to regulate their alcohol or tobacco or gambling, all of which we accept are addictive. In fact, in the case of alcohol, we raised the age from 18 to 21 because we thought even 18-year-olds weren't able to do it. And yet somehow for this behavior, we think of it as just so different that it doesn't require greater cognitive capacity. And I don't believe that. Yeah, very good point. Kris, let me ask you a question about how you and your colleagues at Children and Screens set priorities because there are a lot of things that one could potentially worry about as outcomes. There's violence that kids see on social media. There's cognitive and brain development, social developments, social interactions, and bullying. Mental health, body image, diet, all these things are out there. How do you decide what to work on? Well, we try to work on all of it. And in fact, we've built up a fair amount of expertise and resources around almost 25 different topics. And we also understand that, you know, childhood is a long period of time. Birth to 18, birth to 21, birth to 25, depending on who you talk to. So, we're able to take those 25 topics and also provide deeper, you might say, resources that address the different stages of development. We're really trying to do as much as we can. What's been interesting over these last few years is trying to figure out when to be reactive, when to be proactive. And by being proactive, we go out looking for the research, translating it, digesting it, and creating materials with it that we think are really accessible and actionable. At the same time, as Dimitri points out, there are policy windows and there are opportunities that present themselves that you have to react to. If you just only talk about what you want to talk about to each other you're missing some of these external opportunities to inform policy and policy makers. Help influence the way that parents and providers are talking about the issue. Framing it in such a way that engages youth and makes them want what we want for them. We're really excited by increasing opportunities to partner in coalitions with others that care about kids and teachers and nurses and doctors. But we also are speaking directly to leaders in states and school districts at the federal level, at the local level. You would be, I'm sure, not surprised to hear that we are contacted every day by groups that support parents and families. Asking for resources, asking for support, because they're seeing the impact now over many years on their children, their development. Their academic ability. Their cognitive and analytical ability. Their social emotional ability. Their ability to pay attention to tasks that we all know are critical in building that foundation for essentially, you know, future success. The Institute is being pulled in many directions. Ee try really hard to be strategic about what are people asking us for? What does the research say and how can we get that to them as quickly as possible? Dimitri - Can I add to that? You know, I want to emphasize that the concern around the effects of screen use on children's lives is shared by parents on both sides of the aisle. 75% of parents are concerned about the impact of screens on their children's lives. 35% of teenagers are concerned about their dependents on screens and that it has a negative effect on their lives. Actually by some studies, some surveys, even more than 35 to 50% of teenagers are concerned. And both sides of the political aisle agree in large part of this. And Kris and Kelly, you guys are the policy wonks, you can speak more to that. So it's a serious indictment on us as grownups and as a society that we have not done more to deliver on this issue. Why? When there's bipartisan agreement amongst many policymakers. This is not a political [00:22:00] issue to speak of and there is widespread concern on the part of parents and even teenagers. Why is nothing happening? Well, one has to look no further than where the money is. And that's a problem. I mean, that's a serious indictment on our political system when we can't deliver something that is needed and basically wanted by everybody but the industry itself. We'll come back and talk in a few moments about the policy issues and where industry gets involved here. But let me take just a bit of a detour from that and talk about the book that I mentioned earlier, because I think it's such a valuable resource. Now, when I mention the name of this book I'm urging our listeners to write this down or to remember it because you can get the book at no cost. And I'll come back, Kris, and explain what made that possible and why the decision was to make this an open access book. But Dimitri, let's begin with you. So you, along with Lauren Hale, edited this book that's entitled, The Handbook of Children and Screens: Digital Media Development and Wellbeing From Birth Through Adolescence. I think it's an extraordinary piece of work, but tell, tell us about the book.  It was an extraordinary undertaking. There's I think 178 or 180 authors. Literally, it's a who's who of experts in children and media research in all disciplines. It represents pediatrics, psychiatry, psychology, communications experts, demography, lawyers, neuroscientists. I don't know who I'm forgetting. Every single discipline is represented. Leading scientists in all of those areas. Virtually every topic that someone might be of interest to people. And we deliberately made the chapters short and easily accessible. So, it is, I think, a great resource for the constituents we serve. For teachers, for parents, for researchers, for policymakers. And it is free. The hardest part of it, to be honest, as an editor, was getting peer reviewers because unfortunately, every expert was conflicted since they all had an article in it. But it was a long time coming. And again, this was really the brainchild of Pam (Pamela Hurst-Della Pietra) and we're grateful to have brought it along. So, you go all the way from the neuroscience, how children's brains are reacting to this, all the way out there into the public policy and legal arena about what can be done about it. And then kind of everything in between. It's remarkable how much the book covers. It's almost a thousand pages. I mean, it is a tome to be sure. And don't forget to mention, Dimitri, we aren't even two months post publication, and we have 1.6 million views of the document, despite its gargantuan size. I think that is really a tribute to experts like you and others that have really studied this issue and can speak directly to its impacts. It's been great to see the success so far. You know, not a small number of those views is from me logging on. And then a million from me and then we got there. So, it is free because it's online and you can download it. You can also order a hard copy for I think, $60, but I'm not sure why you would do that if you can download it for free. But it's up to you. So, Kris, it's unusual for a book like this to be made open access and free to the general public. What made that possible and why was that so important? We want the maximum number of people to use it and treat it like the premier resource that it is. And the only way you can really do that is to fund it to be open access and find a publisher that does open access publishing, which we did with Springer. I mean, most journal articles are behind a paywall and publishers do require you to purchase either a subscription or the document itself to download it or order it. And we just really wanted maximum access. So, we funded it to be published in that way. And I think honestly, it helped us even sort of create it in the first place. People want to be a part of something that has that level of access and is available so widely. So, I think it was a kind of mutually beneficial. It gets more people to read it, but it got more people to write for it too, I think. Right, Dimitri? Dimitri - I agree. I mean, you know, the numbers 1.6 million are extraordinary. I mean, Kelly, you've been internal editor. I mean, as a editor of JAMA Pediatrics, if an article gets 70,000 views, it's in our top 1%, you know, 200,000 views is 0.01%. 1.6 million in growing is really extraordinary. And that's about the number of people that read my articles. 1.6. And of course, they're not all scientists. I mean, many of them are parents and maybe are policy makers, but that's Kris's point, you know. The moment anyone hits a paywall, even if it's a dollar or two, they're going to walk away. It's great to see it get so much traction. Alright, so again, for our listeners, the title of the book is The Handbook of Children and Screens. And it's really a terrific resource. Alright, so let's turn our attention to a really important matter. And we've sort of touched on this, but who's in charge of protecting our children? You know, Dimitri at the end of the day help survey this landscape for us. I mean, is it congress, is it the administrative branch of government? What role do the courts play? Are there legal actors taking meaningful action? What's being done does it come anywhere near, meeting the need. Tell us about what that landscape is like? Well, there isn't adequate protections for children. And we talked a little bit about that earlier. There's been an enormous loophole, unfortunately, created by Congress when they added the Section 230 to the Communications Decency Act in 1996. And that was put in place essentially to provide protections for internet companies. And it basically said that they should be treated like bookstores and not publishers. That they weren't responsible for content they were just conveying it. And what that means, in effect, was that the companies had sort of carte blanche to do whatever they want. And they've used that very effectively, legally, to argue that any restriction, any culpability on their part, is protected by that Act. That they're exonified for any ill that occurs as a result of their product. The only exception that's been made of it, to date, was around sex trafficking on back page, if anyone remembers that. But other than that, social media sites and internet sites in general have been able to say that they're not liable for anything that's done. And I think that was a huge mistake that was made. It needs to be rectified. It's being challenged in the courts presently. My own belief is that, and I'm not speaking as a lawyer, is that when that law was passed, it was under the assumption as I said, that they were just conveying information. No one at the time foresaw the development of algorithms that would feed the information. It's really not a bookstore when you are making recommendations. Once you start recommending things, I think you're no longer merely a purveyor of product. You're actually pushing it. So, Kris, tell us about the Children and Screens and the role the organization plays in this space. And how do you deal with policy and is it possible to be bipartisan? Yeah, I mean, it's essential. There's no way to get anything done, anywhere on these policy matters at a population level without working in a bipartisan or non-partisan manner, which is what we've always done. And it's easy to do that when you're following the science, not ideology. And you're putting the science first and you're creating resources and tools and support for those mostly staffers, honestly, that are trying to help their bosses get smarter and better at talking about these issues as they evolve and become more complicated over time. It takes more effort to staff a lawmaker on this front. And they're very anxious to learn and understand because they're meeting with parents of children who have been harmed. Or frankly didn't even survive their childhood because of the social media platform. There's great urgency on the part of policymakers. We've heard everything from school phone bans to outright social media bans proposed as policies. And one thing I like to come back to is it's one thing to want to take action and make your best guess at what would have the best impact. But it's another thing to study whether or not that policy actually achieved its result. And it's a part of this that by staying bipartisan, nonpartisan allows us to say, 'Hey lawmaker, if you're able to get that to happen, we'd really like to come in and help study whether or not your idea actually achieves the results that you wanted, or if it needs to be adjusted or amended over time.' Fantastic. That's so important to be doing that work, and I'm delighted the organization is doing it. Let me ask a question here. If you think about some of the areas of public health that I've been following, like tobacco, for example. Opioids more recently. Vaping products. And in the case of my own particular work food policy. The administrative legislative branches of government have been almost completely ineffective. If I think about food policy over the years, relatively little has been accomplished. Even though lots of people have worked really hard on it. Same thing happened with tobacco for many years. Opioids, same thing.  And it's until you get the third branch of government involved, the judiciary, and you start suing the actors who were causing the harm do you get much action. Not only do the lawsuits seem to have an effect, but they soften the ground for legislative things that then can occur because public opinion has changed. And then those things help make a difference as well. What do you think about that kind of issue in this space?  I think you're exactly right. I mean, I think the failure of our legislative branch to enact policy leaves us with very few options at this point anyway, except to try to pursue it through the judiciary. There are challenges there. First and foremost, it's a big and well-funded industry, not unlike tobacco or big food, as you mentioned and there's this Section 230 that's given them kind of blanket immunity to date. But there are many, many very large pending cases in several jurisdictions brought by individuals, brought by school districts, brought by states. And those, at least provisionally have gotten further than prior cases have with which have been thrown out based on Section 230. So, we'll see what happens with that litigation. But right now, my guess is it's the best chance we have to set some guardrails. And I think there are plenty of guardrails that could be set. Everything that these companies have done to make their products addictive can be undone. Can be made protective. The tobacco company deliberately designed their products to be addictive. While they tried to make the claims that they were less addictive, you know. They made light cigarettes that had holes in the filter so that it would diffuse the carbon and nicotine, but people quickly learned they could cover those up with their fingers and think they were smoking light cigarettes, and smoke more of them. There's a lot of things that can be done in this space to undesign the problematic nature of the products. And quite apart from the financial settlements, which will get companies attention, I hope that that's part of any settlement if it gets that far. It'll be interesting to see where those go. And, also historically, one important part of these lawsuits is what gets turned up in discovery. And what sort of intent the companies have and how much do they know about harms. And how much do they know about addiction and things like that. And how they might have proceeded in the face of that information that then doesn't get disclosed to the public. In any event, we'll see where that goes. Dimitri, what about the argument that responsibility resides with parents. It's up to parents to protect their kids from this, and government doesn't need to be involved. I've never understood that argument. I mean parents obviously are children's most important safeguard, but as a society, we enact policies and laws to assist parents in that. I mean to me, if I made the argument, well, why, why do we have minimum ages of drinking. It's parents' job to make sure their kids don't drink. How would that possibly play out? Look, it's hard enough as a parent anyway, because kids do get around these laws. But we still have them and it's a lot easier as a parent. I think most parents would agree their life's made easier by minimum age restrictions on certain things. We have seatbelt laws. I mean, why do we have seatbelt laws? Why don't we just tell its parents' job to make sure their kids buckle up? The truth is its society and parents working hand in hand to try and keep children safe. And I think it also helps parents to be able to say that there are laws around this, and I expect you to follow the laws. So, I don't think it's an either or. Okay, well, I think that's a very good way to frame it. There are many, many precedents where we protect children. And why not do it here too? So let me end with a question I'd like to ask both of you. So, in this sea of concerns that we've discussed, is there a reason for optimism? And Kris, let me start, start with you. What do you think? Absolutely. I think the young people I've met that are leading among their peers are incredibly impressive and are armed with the research and their energy and their own lived experience in ways that are very compelling. At the same time, I think the vast amount of research that has now been compiled and translated and acted upon, whether in courtrooms or in state houses, it's becoming more, and we're all getting more steeped and aware of more nuanced information. And finally, I would just say, there is a tipping point. We are reaching as a society, adults and kids alike, we are reaching a tipping point where we can't withstand the pressure of technology in every aspect, every corner of our day, our life. And we want relief. We deserve relief. And I think that's what's going to take us over the finish line. Good. Well, I'm glad to hear those optimistic notes. Dimitri, what about you? I can find reasons to be optimistic. I mean, look, the reality is that technologies have enriched our lives in many ways. And I think if we put guardrails in place, we can make sure that future ones do even better. I have a piece coming out in JAMA Pediatrics around the use of AI, which people are very concerned about, I think rightly. But specifically, about the use of AI and people with intellectual developmental disabilities, making the use case, that there are ways in which it could be extremely beneficial to that population. A population I care deeply about in my role as the Chief Health Officer at Special Olympics International. And in particular, let's say in terms of the doctor patient interaction where it could facilitate their communication with their provider, and it could also help the provider better communicate with them. Look, that use case isn't going to be a priority for the purveyors of artificial intelligence. It's a small, non-lucrative use of a technology. But it's a good one. And if we created the right incentives and put in the right guardrails, we could find many other ways that technology can serve the needs of all of us going forward. I think the problem is that we've tended to be reactive rather than proactive. And to not start with the do no harm first premise, particularly when it comes to children. AI is another example of that where I hope we don't make the same mistake we made with social media. Bios Kris Perry is the executive director of the Children and Screens Institute. Kris most recently served as Senior Advisor to Governor Gavin Newsom of California and Deputy Secretary of the California Health and Human Services Agency where she led the development of the California Master Plan for Early Learning and Care and the expansion of access to high-quality early childhood programs. She led systems change efforts at the local, state and national levels in her roles as executive director of First 5 San Mateo, First 5 California and of the First Five Years Fund. Through it all, Perry has fought to protect children, improve and expand early learning programs, and increase investments in low-income children. Perry was instrumental in returning marriage equality to California after the landmark 2013 U.S. Supreme Court ruling Hollingsworth v. Perry, which she wrote about in her book Love on Trial (Roaring Forties Press, 2017). Dimitri Christakis, MD, MPH is the Children and Screens Institute's inaugural Chief Science Officer. He is also the George Adkins Professor at the University of Washington, Editor in Chief of JAMA Pediatrics, and the Chief Health Officer at Special Olympics International. Christakis is a leading expert on how media affects child health and development. He has published over 270 peer reviewed articles (h-index 101) including dozens of media-related studies and co-authored a groundbreaking book, The Elephant in the Living Room: Make Television Work for Your Kids. His work has been featured on Anderson Cooper 360, the Today Show, ABC, NBC, and CBS news as well as all major national newspapers. Christakis received his undergraduate degree at Yale University and his medical training at the University of Pennsylvania School of Medicine and completed his residency and Robert Wood Johnson Clinical Scholar Fellowship at the University of Washington School of Medicine. 

Roughly 80% of perimenopause and menopause symptoms are brain-derived. From mood swings to low-stress tolerance, insomnia, and more… are you taking care of your brain during this huge transition period in midlife?  It's no wonder one of the biggest concerns of women over 40 is their mental health. So, if you're experiencing anxiety, overwhelm, brain fog, and irritable mood, you're NOT alone.  That's why Dr. Drew Ramsey is joining me on the podcast today to share his expertise on mental health and teach you how to feel safe in your body and brain.  We talk about:  What the modern brain is, and what you can do for optimal brain health in today's world  Tackling obstacles when it comes to caring for your mental health Must-do habits for your brain that you can easily start ASAP And MORE Don't miss this episode– because with the right mental fitness, you'll start to feel like yourself again, and stay that way for good! Drew Ramsey, MD Dr. Drew Ramsey is a board-certified psychiatrist, author, and mental health advocate who founded the Brain Food Clinic– a digital mental health clinical practice. He's written several books that explore the connections between mental health and nutrition. He's also on the Advisory Board at Men's Health, the Editorial Board at Medscape Psychiatry, and the Scientific Advisory Board of the anti-stigma nonprofit Bring Change To Mind. IN THIS EPISODE Prioritizing mental health in our modern world  The science behind movement for mental health  The impact past traumas have on your stress response  Implementing mental fitness for the whole family  Overcoming common obstacles when improving mental fitness  The power of journaling for your mental health Practical steps for healing your brain and improving mental fitness QUOTES “I don't want mental fitness in any way to be oppressive. My idea is that it's inspirational because it feels good.” “I'm a big advocate of therapy, not just for symptom control and because you're struggling with mental health, but for mental fitness for this notion of an ongoing kind of maintenance and attention to your mind, your mental health, and your specific goals.” “This transition in the 40s, 50s, and 60s into the next chapters of life– being more intentional, being more clear about the challenges for each of us… I think it helps us have a little more grace and feel more oriented.” RESOURCES MENTIONED Get Dr. Ramsey's Book: Healing the Modern Brain Dr. Ramsey's Website Dr. Ramsey's Instagram RELATED EPISODES  594: What I Did This Past Year to Heal My Brain and Lower Systemic Inflammation 586: What You Can Do in Perimenopause to Optimize Your Energy, Resilience and Brain Power with Dr. Mariza #469: Six Powerful Ways to Keep Your Brain Young and Clear #476: How to Pivot in Perimenopause to Increase Energy, Metabolism and Brain Power

Rare condition research is evolving, and patient communities are driving the breakthrough. In this special Rare Disease Day episode, we explore the challenges and opportunities shaping the future of rare condition therapies. From groundbreaking gene therapy trials to the power of patient-driven research, our guests discuss how collaboration between families, clinicians, researchers, and regulators is paving the way for faster diagnoses, equitable access to treatments, and innovative approaches like nucleic acid therapies and CRISPR gene editing. With insights from Myotubular Trust, we follow the journey of family-led patient communities and their impact on advancing gene therapy for myotubular myopathy - showcasing how lived experience is shaping the future of medicine. However, while patient-driven initiatives have led to incredible progress, not every family has the time, resources, or networks to lead these research efforts. Our guests discuss initiatives like the UK Platform for Nucleic Acid Therapies (UPNAT), which aims to streamline the development of innovative treatments and ensure equitable access for everyone impacted by rare conditions. Our host Dr Ana Lisa Tavares, Clinical lead for rare disease at Genomics England, is joined by Meriel McEntagart, Clinical lead for rare disease technologies at Genomics England, Anne Lennox, Founder and CEO of Myotubular Trust and Dr Carlo Rinaldi, Professor of Molecular and Translational Neuroscience at University of Oxford. "My dream is in 5 to 10 years time, an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested. And at that exact time, the day of the diagnosis becomes also a day of hope, in a way, where immediately the researcher that sent the genetics lab flags that specific variant or specific mutations. We know exactly which is the best genetic therapy to go after." You can download the transcript, or read it below. Ana Lisa: Welcome to Behind the Genes.    [Music plays]  Anne: What we've understood is that the knowledge and experience of families and patients is even more vital than we've all been going on about for a long time. Because the issue of there being a liver complication in myotubular myopathy has been hiding in plain sight all this time, because if you asked any family, they would tell you, “Yes, my son has had the odd liver result.”  There were some very serious liver complications but everybody thought that was a minor issue, but if we are able to engage the people who live with the disease and the people who observe the disease at a much more fundamental level we may be able to see more about what these rare genes are doing.  [Music plays]  Ana Lisa: My name is Ana Lisa Tavares, I'm Clinical Lead for Rare Disease research at Genomics England and your host for this episode of Behind the Genes. Today I'm joined by Anne Lennox, Founder and CEO of the Myotubular Trust, Dr Meriel McEntagart, an NHS consultant and Clinical Lead for Rare Disease Technologies at Genomics England, and Dr Carlo Rinaldi, Professor of Molecular and Translational Neuroscience at the University of Oxford.    Today we'll be hearing about the importance of involving the patient community, particularly as new rare therapies are developed, and discussing the forward-facing work that's happening that could have potential to unlock novel treatments for many rare conditions.  If you enjoy today's episode we'd love your support. Please like, share and rate us on wherever you listen to your podcasts. Thank you so much for joining me today.  Please could you introduce yourselves.   Anne: I'm Anne Lennox, I'm one of the founders of the Myotubular Trust, a charity that raises research funds for and supports families affected by the rare genetic neuromuscular disorder myotubular myopathy.  Meriel: I'm Meriel McEntagart, I'm a consultant in clinical genetics in the NHS and I have a special interest in neurogenic and neuromuscular conditions.  Carlo: Hi, I'm Carlo Rinaldi, I'm Professor of Molecular and Translational Neuroscience at the University of Oxford. I'm a clinician scientist juggling my time between the clinic and the lab where we try to understand mechanisms of diseases to develop treatments for these conditions.  And I'm also here as a representative of the UK Platform for Nucleic Acid Therapies, UPNAT. Thanks for your invitation, I'm very pleased to be here.  Ana Lisa: Thank you. Meriel, I'd love you to tell us a bit about your work and how you met Anne, how did this story start?  Meriel: Thank you. Well prior to being a consultant in clinical genetics, I spent 2 years as a clinical research fellow in neuromuscular conditions, and as part of that training I worked on a project where the gene for myotubular myopathy had just been identified, and so there was a big international effort to try and come up with sort of a registry of all the genetic variants that had been found as well as all the clinical symptoms that the affected patients had, and then do kind of a correlation of the particular variant mutation with symptoms.   I worked when I was training to be a clinical geneticist because of my interest in neuromuscular conditions so when I eventually became a consultant at St George's Hospital I was actually interviewed by the Professor of Paediatrics and he knew Anne and her son, when Anne was looking for more information about the condition he suggested that perhaps I might be a good person for Anne to talk to.  Ana Lisa: Thank you. Interesting connections. Anne, can you tell us your story and how this led you to found the Myotubular Trust?  Anne: Yes, thanks Ana-Lisa.  Well, as many families will tell you when they're newly diagnosed with a rare disease, you go from knowing nothing about a condition to being one of the few deep experts in that condition because there are so few deep experts. So this happened to us in 2003 when our son, Tom, was born, and when he was born he was floppy and his Apgar scores, the scores they do on new-born babies, were pretty poor, and before long we knew that it was more than just momentary issues at birth.  And, cutting a very long story short, 5 weeks later he was diagnosed with this very rare neuromuscular genetic disorder that we didn't know we had in the family.  We were told that this was a very serious diagnosis.    At that time – more than 20 years ago – over 80% of those boys didn't make it to their first birthday and the stark statistic we had in our head a lot was that only 1% made it past the age of 10. And that has changed due to better ventilator and breathing equipment, etc, but at the time we expected that he might not make it to his first birthday.    We were very lucky, we had Tom longer than one year, we had him for nearly 4 years, 4 very lovely years where it was tough, but he was a really lovely member of our family.  Despite being really weak he managed to be incredibly cheeky and bossy, and he was a great little brother for his big sister. We were also very lucky that he was being looked after by Professor Francesco Muntoni, who is Head of the Paediatric Neuromuscular Service at Great Ormond Street. And, like Carlo, he is a clinical researcher and actually that I found to be amazing as a family member because you knew what was happening out there and Professor Muntoni, other than living with the reality day to day you want to know where things are going.    We began to realise that back then 20 years ago the more common rare neuromuscular diseases were finally beginning to get some fundamental research funds, like Duchenne, spinal muscular atrophy, and Professor Muntoni was very good at explaining to lay non-scientific parents like us that one day the technologies that would lead to a cure, that would re-engage proteins for other conditions and would translate down eventually into the possibility of replacing myotubularin, which is the protein not being produced or not being produced enough in myotubular myopathy. And then we began to understand actually what the barriers to that would be, that translating developments in more common, or let's say more prevalent conditions, would be hard to do without some translation research being done; you could not just not lag years behind, you could lag decades behind if you haven't done some other work.    So, I met Wendy Hughes, another mother, of a boy called Zak who was a few years older than Tom, and these were the days before social media, and it was amazing to be in contact with another family going through something similar and we had great conversations. But then they were also looked after by Professor Muntoni and we particularly began to develop the idea as 2 families that we might be able to raise some research funds towards this concept of keeping pace with the scientific developments.  And then we discovered there was no charity we could channel those funds through. Even the umbrella body for neuromuscular diseases who were covering 30 to 40 conditions, frankly, they just couldn't trickle their funding down into investing in every neuromuscular disease, and slowly but surely it dawned on us that if we did want to make that difference we were going to have to set up our own charity.   So that's what we eventually did and back in 2006, we founded what was actually the first charity in Europe dedicated to myotubular myopathy – luckily, more have come along since – and we were dedicated to raising research funding. In fact, it wasn't our goal to set up another charity but around that time, about a year in, we happened to go to a meeting where the Head of the MRC, the Medical Research Council, was giving a talk and he said that in the last few years the MRC had begun to really realise that they couldn't cure everything, that they couldn't cure the diseases that would be cured in the next millennium from a top down perspective. There had to be a trick, there had to be a bottom up as well, because that was the only way this was going to happen. And I have to say that that was a really reassuring moment in time for us to realise that we weren't just chasing pipe dreams and trying to do something impossible, that there was a role for us.    Ana Lisa: I think it would be really interesting for people to hear your story and the amazing set-up and fundraising that you've done, and at the same time it would be really good for us to reflect on how this isn't feasible for every patient and every family and how we're going to need to work cooperatively to move forwards with rare therapies.  Anne: When we explored the idea with Professor Muntoni and Meriel and others about setting up a charity one of the really reassuring things that Professor Muntoni got across to us was that this wasn't about raising the millions and millions it would take to fund clinical trials but the issue in the rare disease space was funding the proof of principle work, the work where you take a scientist's hypothesis and take it over the line, and the rarer the disease, the less places there are for a scientist to take those ideas. And the example he gave us was a piece of research like that might cost a hundred to a couple of hundred thousand, if you fund a piece of work like that and if it is successful, if the scientist's principle gets proven, then behind you it's much easier for the bigger muscle disease charities to also invest in it. It's harder for them to spread their money across all the very rare diseases hypothesis out there, but if you've helped a scientist get over the line they'll come in behind you and then they won't be the ones who fund the tens of millions that it takes to run a clinical trial.    If it's got potential, then that's where the commercial world comes in, and that's where the biotechs come in. So he'd given the example of if you spent £ten0,000 on a piece of research and it actually is proven, in behind you will come the bigger charities that would put in the million that takes it to the next phase, and in behind them will come the bio-checks that'll provide biotechs that'll provide the tens of millions.    And then, you know, a lot of what happens relies on serendipity as well, we know that, and you could easily run away with the idea that you made everything happen but you don't, you stand on the shoulders of others. And our very first grant application in our first grant round, which received extraordinary peer review for how excellent the application was, was a £100,000 project for a 3-year project that had gene therapy at the core of it by a researcher called Dr Ana Buj Bello at Généthon in Paris. This piece of research was so promising that 18 months in she and another researcher were able to raise $780,000 and, as Professor Muntoni predicted, from the French muscle disease charity AFM and the American muscle diseases charity MDA.  And 18 months into that 3 years it was so promising that a biotech company was started up with $30 million funding, literally just on her work.    So that doesn't always happen but, as Professor Muntoni explained, our job was not that $30 million, our job was that first £100,000, and our job was also to make ourselves known to the people in the neuromuscular field.  If you have lab time, if you have research time and you have a choice where you're putting it there is a place you can go to for a myotubular myopathy related grant application, so it's not just that this will come to us out of the blue, people will have done prior work, and our existence makes it worth their while, hopefully, to have done that prior work.  Ana Lisa: That's an amazing story how you've set up this charity and how successful that first application for gene therapy was. I'd love to hear more about that gene therapy and did it get to the clinic and to hear that story from you.  Because I think there are a lot of learnings and it's really important that the first patients who are treated, the first families that are involved, the researchers who start researching in this area, the first treatments lead the way and we learn for all the other treatments for all the other rare conditions that we hope and that together as a community we can share these learnings.  Anne: Yeah. I sometimes describe it a bit like going out into space. When you see a rocket going off look at how many people are behind and the amount of work that's been done, the degree of detail that's managed, and then you go out into space and there are a whole load of unknowns, and you can't account for all of them.  Who knows what's out there in this sphere.  But the amount of preparation, it feels similar to me now, looking back.  We were so idealistic at the beginning.  Our grant to Dr Buj Bello was 2008 and actually it is a really fast time in, the first child was dosed in the gene therapy trial in September 2017.  Ana Lisa: So, we're talking less than 1 years.  Anne: Yeah. And in the meantime obviously as a charity we're also funding other proof of principle research. One of the founding principles of the charity was to have a really excellent peer review process and scientific advisory board so that we wouldn't get carried away with excitement about one lab, one research team, that everything would always come back to peer review and would be looked at coldly, objectively. I don't know how many times I've sat in a scientific advisory board meeting with my fingers crossed hoping that a certain application would get through because it looked wonderful to me, and then the peer review comes back and there are things you just don't know as a patient organisation. So, yes, in those 9 years we were also funding other work.  Ana Lisa: You've just given an interesting perspective on sharing the learnings between the scientists, clinicians, the experts in a particular condition, if you like, and the families, and I'd be really interested to hear your views on what's been learnt about how families and the patient community can also teach the clinical and scientific community.  Anne: So, the first child was dosed in September 2017 and by the World Muscle Society Conference 2 years later in October 2019 the biotech had some fantastic results to show. Children who had been 24-hour ventilated were now ventilator-free, which, unless you know what it's like to have somebody in front of you who's ventilator-dependent, the idea that they could become ventilator-free is just extraordinary.    However, one of the things we've learnt about gene therapy is that we are going out into space so there are extraordinary things to be found, and extraordinary results are possible, as is evidenced here, but there is so much that we don't know once we are dealing with gene therapy. So unfortunately, in May, June and August of 2020, 3 little boys died on the clinical trial. So we have a clinical trial where the most extraordinary results are possible, and the worst results are possible, and both of those things are down to the gene…  What we discovered and what is still being uncovered and discovered is that myotubular myopathy is not just a neuromuscular disorder, it is a disorder of the liver too, and these children didn't die of an immune response, which is what everybody assumes is going to happen in these trials, they died of liver complications.    And one of the things that has come out of that, well, 2 sides to that. Number one is that it is extraordinary that we have found a treatment that makes every single muscle cell in the body pick up the protein that was missing and produce that protein, but also what we've understood is that the knowledge and experience of families and patients is even more vital than we've all been going on about for a long time. Because the issue of there being a liver complication in myotubular myopathy has been hiding in plain sight all this time, because if you asked any family they would tell you, “Yes, my son has had the odd liver result, yes.”    We could see something that looked like it was not that relevant because it was outside the big picture of the disease, which was about breathing and walking and muscles, but actually there was this thing going on at the same time where the children had liver complications. There were some very serious liver complications but everybody thought that was a minor issue but if we are able to engage the people who live with the disease and the people who observe the disease at a much more fundamental level we may be able to see more about what these rare genes are doing.  Ana Lisa: Yeah, thank you very much for sharing such a moving story and with such powerful lessons for the whole community about how we listen to the expertise that families have about their condition, and also I think the really important point about how we tackle the research funding so that we're including and sharing learnings from the conditions that are initially studied in greater depth, and we hope that many more conditions will be better understood and more treatments found and that actually the learnings from these first gene therapy trials will really help inform future trials, not just for gene therapies but also for many other novel therapies that are being developed.  [Music plays] If you're enjoying what you've heard today, and you'd like to hear some more great tales from the genomics coalface, why don't you join us on The Road to Genome podcast. Where our host Helen Bethel, chats to the professionals, experts and patients involved in genomics today. In our new series, Helen talks to a fantastic array of guests, including the rapping consultant, clinical geneticist, Professor Julian Barwell, about Fragile X syndrome, cancer genomics and a holistic approach to his practice - a genuine mic-drop of an interview. The Road to Genome is available wherever you get your podcasts. [Music plays] Ana Lisa: Carlo, I would really like to come to you about some of the initiatives that are happening in the UK, and particularly it would be really interesting to hear about the UK Platform for Nucleic Acid Therapies as a sort of shining example of trying to do something at a national scale across potentially many different rare conditions.    Carlo: Thanks, Ana-Lisa. Thanks very much, Anne, for sharing your fantastic story. I mean, I just want to iterate that as clinician scientists we do constantly learn from experiences and constantly learn from you, from the patient community, and this is absolutely valuable to push the boundary. And I really liked your vision of a rocket being launched in space and I would imagine that this is a similar situation here. So, we are facing a major challenge. So, there is over 7,000 rare diseases in the world and with improvements of genetic diagnosis this is only increasing. So, in a way rare diseases is the ultimate frontier of personalised medicine and this poses incredible challenges.   So, you mentioned the bottom-up approach and the top-down approach and in a way, both are absolutely necessary. So your story is a fantastic story but also makes me think of all the other families where they don't share perhaps the same spirit, you know, they are in areas of the world that are not as well connected or informed, where patient community simply cannot be ‘nucleated', let's say, around the family. So, there is definitely an issue of inclusivity and fair access.    So, what we're trying to do at UPNAT, which is the UK Platform for Nucleic Acid Therapy, is to try to streamline the development both at preclinical and clinical level of nucleic acid therapies. So, we'll start with antisense oligonucleotides just because those are the molecules of the class of drugs that are most ‘mature', let's say, in clinic. So, there are several antisense oligonucleotides already approved in the clinic, we know that they are reasonably safe, we understand them quite well, but of course the aspiration is to then progress into other forms of gene therapy, including gene editing approaches, for example.   And one of the activities that I'm involved, together with Professor Muntoni, is to try to streamline the regulatory process of such therapies and in particular curate a registry of, for example, side effects associated with nucleic acid therapy in the real world, and you would be surprised that this is something that is not yet available.  And the point is exactly that, it's trying to understand and learn from previous mistakes perhaps or previous experiences more in general.    And this is very much in synergy with other activities in the UK in the rare disease domain.  I'm thinking of the Rare Disease Therapy Launchpad, I'm thinking of the Oxford Harrington Centre, I am thinking of the recently funded MRC CoRE in Therapeutic Genomics. These are all very synergistic. Our point is we want to try to amplify the voice of the patient, the voice of the clinicians working on rare disease, and we want to systematise. Because of course one of the risks of rare disease therapies is the fragmentation that we do all these things in isolation. And I would argue that the UK at the moment leveraging on the relatively flexible and independent regulatory agencies, such as the MHRA, on the enormous amount of genetics data available through Genomics England, and of course the centralised healthcare system, such as the NHS, is really probably the best place in the world to do research in the rare disease area, and probably I'm allowed to say it because I'm a non-UK native.       Ana Lisa: Thank you, that's a brilliant perspective, Carlo, and across all the different therapeutic initiatives that you're involved with. And, Carlo, presumably - we're all hoping - these different initiatives will actually lead to ultimately a bigger scaling as more and more novel therapies that target both our RNA and DNA and actually are working, I guess further upstream in the pathway.    So classically in the past it's been necessary to work out all the underlying biology, find a druggable target somewhere in that pathway and then get a larger enough clinical trial, which can be nearly impossible with many of the rare and ultra-rare conditions or even, as you've said, the sub-setting down of more common condition into rarer subtypes that perhaps can be treated in different ways.  And with the many new different treatments on the horizon, ASO therapies, as you've said, is a place that's rapidly expanding, and also crisper gene editing. I'd be really interested to hear your reflections on how this might scale and also how it might extend to other new treatments.  Carlo: Yeah, that's exactly the right word, ‘scaling up'. I mean, there will be of course very unique challenges to every single rare disease but I would argue that with genetic therapies, such as ASOs or crisper gene editing, the amount of functional work that you need to do in a lab to prove yourself and the scientific community that this is the right approach to go for can be certainly very important but can be less just because you're addressing very directly because of the disease.    And then there are commonalities to all these approaches and possibly, you know, a platform approach type of regulatory approval might serve in that regard. You know, if you are using the same chemistry of these antisense oligonucleotides and, you know, similar doses, in a way the amount of work that you need to produce to again make sure that the approach is indeed a safe approach and an effective approach might be also reduced.    I would say that there are also challenges on other aspects of course, as you were saying, Ana-Lisa. Certainly the typical or standard randomised placebo control trial that is the standard and ultimate trial that we use in a clinical setting to prove that a molecule is better than a placebo is many times in the context of rare diseases simply not possible, so we need to think of other ways to prove that a drug is safe and is effective.   This is something that we all collectively as a scientific community are trying to address, and the alliance with the regulatory agencies, such as the MHRA, and you said that you have found your interaction with the MHRA very positive, and I can tell you exactly the same. So we are all trying to go for the same goal, effectively, so trying to find a way to systematise, platformise these sort of approaches. And I guess starting with antisense oligonucleotides is really the right place to go because it's a class of drugs that we have known for a long time, and we know it can work.  Ana Lisa: Meriel, can you tell us a little about the National Genomic Research Library at Genomics England and how this could link with initiatives to find many more patients as new treatments become available for rare and ultra-rare conditions?  Meriel: Yes, I think what's wonderful now is actually that what we're really trying to do is give everybody the opportunity to have their rare condition specifically diagnosed at the molecular level, and the way in which that is being done is by offering whole genome sequencing in the NHS currently in England but to all patients with rare diseases.    And so, it's about trying to establish their diagnosis. And as well as that, even if the diagnosis isn't definitely made at the first pass when the clinical scientists look at the data, because the whole genome has been sequenced, actually all that information about their genome, if they consent, can then be put into the National Genomics Research Library.  And that is a fantastic resource for national and international researchers who get approved to work in this trusted research environment to make new disease gene discoveries and identify these diagnoses for patients.  What's also offered by Genomics England as well is when the National Genomics Library data results in a new publication, the discovery of a new gene or perhaps a new molecular mechanism that causes a disease we already know about, that feeds back into the diagnostic discovery pathway within Genomics England back onto the diagnostic side of all the data.    So, patients who may have had genetic testing previously using whole genome sequencing where they've, if you like, had their sequencing done before the diagnosis was sort of known about, will also be picked up. And so, what this is really doing is trying to kind of give this really equal platform for everybody having testing to all have the same opportunity to have their diagnosis made, either on the diagnostic side or with research.  Ana Lisa: So, sort of on a cohort-wide scale as new discoveries are made and published you can go back and find those patients that may actually have that diagnosis and get it back to them, which is brilliant.  Meriel: Exactly. And this speeds up the whole process of getting these diagnoses back to people. So on a regular basis in the NHS, we will get feedback from the Diagnostic Discovery Pathway about “Here's some patients who you requested whole genome sequencing from a number of years ago and actually now we think we know what the particular molecular condition is.”  And so, it's key of course for our patients with rare conditions to make that molecular diagnosis because then we're able to have them identified for our colleagues who are doing this ground-breaking research trying to bring therapies for these rare conditions.  Ana Lisa: Thank you. And I hope that, as currently, if a novel genetic mechanism, as you've just described, is identified that could explain a rare condition that those patients can be found and they can receive that diagnosis, even many years later, and hopefully as novel treatments become available and say there's a chance to individualise ASO therapies, for example, to start with, that one could also go and look for patients with particular variants that could be amenable potentially to that treatment. And that's really sort of exciting that one could look for those patients across England, irrespective of which clinic they're under, which specialist they're under, and I think that could be really powerful as new treatments develop. I suppose, Meriel, if somebody comes to see you now in clinic are things different?  Meriel: Well, I think one of the things for me when patients come to clinic now is we might have an idea about what we think their condition is, maybe even we think it's a specific gene. And we can offer whole genome sequencing and so it's not just the way we used to do things before by looking just at the coding regions of the gene, we can find more unusual ways in which the gene can be perturbed using whole genome sequencing.  But let's say we don't make the diagnosis. I encourage my patients, if they're comfortable with it, to join the National Genomics Research Library, because really it's been incredibly productive seeing the new genetic discoveries that are coming out of that, but as well I say to them, even if we don't get the diagnosis the first time round when we look at the data, actually this is a constant cycle of relooking at their data, either if they're in the NGRL or as well on the Diagnostic Discovery Pathway side of the service that's run by Genomics England. So yeah, I feel like it's a very big difference; they don't have to keep coming every year and saying, “Is there a new test?” because actually they've had an excellent test, it's just developing our skills to really analyse it well.  Ana Lisa: Yes, and our knowledge, the technology and the skills keep evolving, certainly.  And I think one of the things that I'm sort of hearing from this conversation is that balance of hope and realism, Carlo we were talking about earlier how you need all the pieces of the puzzle to be lined up - so the regulatory agency, the clinicians, all the preclinical work has to have been done, monitoring afterwards for side effects - every piece of the puzzle has to be lined up for a new treatment to make it to a patient.    And, Anne, I'd like to come back to you because we've talked about this before, how one balances these messages of optimism and hope which are needed for bringing everybody together as a community to crack some of these very difficult challenges highlighted by treatments for rare and ultra-rare conditions and at the same time the need for realism, a balance conversation.  Anne: Yeah, that was one of our big learnings through the gene therapy trial and other trials we've had in the condition. As a rare disease charity, you do everything. You know, my title is CEO, but I tell people that's Chief Everything Officer because there's only a few of you and you do everything. So, you go and you lead the London Hope Walk and you also are a layperson on the Scientific Advisory Board and you also send out the emails about grants... And so, you could easily as a small rare disease charity conflate different communication messages because you're in a certain mode.  And so we have been from the early days in the mode of raising hope for people to say, “Look, we can make a difference as a patient community, we could raise funds, we might be able to move things forward, you've got the power to make a difference if you want to.” That's one set of hope.  And it's not dreamlike hope, we're linked to the reality of there are great breakthroughs.  So, you know, in the world of spinal muscular atrophy these clinical trials have led somewhere very quickly, so we're not selling false hope, we're talking about the difference we can make.    But then as soon as you flip into “There's a clinical trial being run” that's a completely different type of communication and you cannot conflate that message with the previous message.  And we always say to everybody, “We're your team, we're a family, we're a team, we all help each other.  When you are considering joining a clinical trial your team is the clinical trial team.    The other team does other things for you but the people you need to work with and ask hard questions of and listen hard to, that's your clinical trial team led by the principal investigator because then you're in that with them. And, you know, the reality of the fact that many, many clinical trials don't work as we wish they would be and the decision you make for your child, your baby, your little one, to join a clinical trial… because that's what it comes down to in our disease, has to be made with that team, not the team that's selling you a fundraising event. It's worth reminding rare disease patient organisations we're wearing different hats and the hope and the realism are different tracks you have to go down.    But at the same time as being realistic you also have to keep remembering that there is still grounds for hope, we are moving forward. And 21 years ago, when Tom was born the idea that you would be able to get all of the muscles in the body to switch back on – putting it in lay terms – seemed like a bit dream. Well, that is what has happened in the gene therapy clinical trial, we just have to now make it safer and understand more about what we're dealing with. So, the 2 things, the hope and the realism, do exist side by side.  Ana Lisa: I think that perfectly encapsulates a lot of the messages around rare disease therapies where there's such hope that novel treatments will really target directly the DNA or RNA to potentially correct the problem across many different rare conditions and therefore actually making treatments one day suddenly available to a much, much bigger population of people with rare conditions than we could've dreamt of 20 years ago or perhaps now, and at the same time this massive need to work cooperatively to all make this as fair, as equitable. Not everybody is going to have the opportunity to fundraise massively to be an expert about their condition, and the importance of sharing these learnings and also really, really listening to the patient community and really, as Carlo was saying, keeping track of side effects, having registries/databases to share these is going to be incredibly important.  [Music plays]  Ana Lisa:  Anne, can you tell us a little about your reflections on equity from the patient community perspective?  Anne: Well I mentioned serendipity early and one of the aspects of serendipity that played into our favour for setting up the Myotubular Trust was that by hook or by crook Wendy Hughes, who set up the charity with me, and I were both able to devote time at that period of our lives to setting up a charity. When my husband, Andrew, and I were told that Tom would more than likely die before his first birthday, one of the decisions we made as a family was that he would never not be with a parent, we would always have someone around, and that kind of meant someone had to give up a full-time job and that was me.  We thought, “If Tom has a few scarce months on the planet, we'll be with him.” And then when Tom lived to be nearly 4, as a family we got used to living on one salary and we were very lucky that we could pay the mortgage that way and run our family that way and eventually that meant I had the time to run the charity.    That doesn't happen that easily, that's a tall order, particularly when you have somebody in the family who has such high needs. And one of the things that I have often thought about is that in the rare disease space we could do with a different funding model for rare disease charities, we could, in an ideal world I have this nirvana that I imagine where there's a fund that you can apply to that is contributed to by the people who make profits out of finding rare disease cures - so the pharmaceutical companies and the biotechs - and there's a fund that they contribute to and that if you have a rare disease and you are willing to set up an organisation that supports families, that raises research funds, that provides a way of hearing the patient voice, then you could apply to that for running cost funds and then you'd be able to run this charity. And then you wouldn't have to rely on whether you live in an area where people will raise money for you or…  We were very lucky that we came across a few great benefactors who would give us money for running the charity, which is actually how we fund it.    All the research money we raise goes 100% into research, not a penny of it goes towards running costs because we have serendipitously found people who will be benefactors for the charity, but we're relying on a lot of good luck for that kind of model to work. And when you look at how much profit is made from developing rare disease treatments and cures – which is fine because that's what puts the passion and that gets people working on it – then why not have an advance fund to run rare disease charities? One of my nirvana dreams.  Ana Lisa: It's good to dream. Indeed, my hope is that there will be some amazing shining examples that lead the way that open doors, make things possible, prove that something can work and how and that then that will enable many other treatments for many additional rare conditions to be added in so that if you've learnt how this particular treatment modality works for this rare condition and there was funding behind it and everything else that's needed that then you can, the learning from that, I'm going to use the word ‘tweak', which sounds minor and could be very major but actually the concept that you can then tweak all those learnings and findings so that that same type of treatment modality could be adapted to treat somebody else with a different rare condition in a different location would be absolutely incredible and really powerful, given that if something like 85% of rare conditions affect less than one in a million people it's not going to be feasible to use the same strategies that have been used in the past for very common conditions.    One of the other big barriers is the cost of developing treatment for ultra-rare conditions.  Where it's a small number of patients that you have and therefore all the challenges that come with monitoring, checking for efficacy, monitoring safety and ultimately funding the challenges are much greater, however if some of these treatment modalities are also going to be used to treat common conditions it might be that actually there's a lot more cross-talk between the nano-rare, ultra-rare, rare and common conditions and that we can share a lot of that learning. I'd love to hear from each of you where you hope we will be for rare disease and rare therapies.  Carlo: Well my dream is that in 5 to 10 years' time an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested, and at that exact time the day of the diagnosis becomes also a day of hope in a way where immediately the researcher, the centre, genetics lab, flags that there are the specific mutations, we know exactly which is the best genetic therapy to go after, antisense oligonucleotides as opposed to CRISPR editing, and a path forward, both at the preclinical and clinical level, to demonstrate and to cure these patients eventually is already laid out in front of the patient.  So, transforming the day of their diagnosis as a day of hope, this is my dream with the next ten years.  Ana Lisa: Thank you, that's a wonderful dream. Meriel, can I come to you?  Meriel: Yes, I think I just want to echo Carlo.  We've had great developments and progress with getting whole genome sequencing into the NHS for testing but what we really need is for it to be fast and efficient and getting those diagnoses established quickly. And we have had that set up now and we're really getting there in terms of speed, but then what we need is exactly what's the next step and actually structure like UPNAT that are developing these processes that we can then say to the patient, “And from there, now that we've established your diagnosis, this is what we have options to offer.”  Ana Lisa: Brilliant. And presumably that if the diagnosis isn't achieved now there is a hope that it will be achieved in the future as well. Anne...  Anne: Well, stepping one hundred per cent into the patient's shoes rather than the scientific side that we don't so much influence....  stepping in the patient's shoes, in 5 years' time I would absolutely love it if we were in a situation where all the parties that have come to the table looking at a therapy or in the earlier research genuinely want to bring the patient voice into the room. As Carlo talked about, there's even going to be more and more and more of these rare diseases, then those voices, those few people who have experience of it, they may be able to shed light on something. Maybe even sometimes don't even know it's a fact that they know but that were brought to the table as passionately as everything else is brought to the table.  [Music plays]  Ana Lisa: We'll wrap up there. Thank you so much to our guests, Anne Lennox, Carlo Rinaldi and Meriel McEntagart, for joining me today as we discuss the collaborative power of working together and look to the future of rare therapies that could have the potential to unlock treatments for many rare conditions. If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app.  Thank you for listening.  I've been your host, Ana-Lisa Tavares. This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand.  

Send us a textBarbara Scolnick, MD is a graduate of Columbia University College of Physicians & Surgeons and board certified in internal medicine and addiction medicine. Barbara developed the ketogenic/ketamine treatment for anorexia as a pathway out of anorexia to help her niece, our former guest Caroline Beckwith, who we hosted on episode 759 of Boundless Body Radio, recover from the disease.Barbara is the author of two seminal articles on the ketogenic diet and ketamine for anorexia, including groundbreaking case studies reporting remission from chronic anorexia nervosa.She is the co-author of the book Exiting Anorexia: A Revolutionary Keto Metabolic Treatment for Anorexia from the Perspectives of the First Patient, the Physician/Researcher, and the Patient's Mother.She is also on the Medical and Scientific Advisory Board of Anor-Exit, an online program that calls for a ketogenic metabolic therapy to reverse eating disorders. The mantra that “all food is good food,” often fails to achieve a sustained recovery, while Ketogenic Metabolic Therapy has been shown to substantially weaken or eliminate the anorexic voice, anxiety, and behavior.Find Barbara Scolnick, MD at-Email- scolnickbarbara@gmail.comhttps://www.anorexit.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes.  As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology.     In this episode you will discover:    Impact of Candida on the Immune System: Understand how candida overgrowth can weaken your immune system and make you more susceptible to infections.  Candida and Chronic Fatigue Syndrome: Learn about the connection between candida and chronic fatigue syndrome, and how addressing candida can improve energy levels.  Mental Health and Cognitive Function: Discover how candida overgrowth can affect mental health and cognitive function, leading to symptoms like brain fog and mood swings.  Dietary Recommendations for Candida: Get insights into the dietary changes that can help manage and treat candida overgrowth effectively.  Role of Parasites in Health: Explore the prevalence of parasites in Dr. Biamonte's practice and his approach to treating them, along with his thoughts on various diets like Keto, Carnivore, and Vegan.     Connect with (guest name)     Website: www.health-truth.com  Facebook:  https://www.facebook.com/The-Biamonte-Center-241435772676317/  YouTube: https://www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ     Connect more with Dr. Kiltz    Website: https://www.doctorkiltz.com/     Keto + Carnivore Support - Group Kiltz Mighty Tribe: https://kiltz-mighty-tribe.mn.co/      Kiltz Cups: https://kiltzcups.com/     Doctor Kiltz Nutritional Solutions: https://www.doctorkiltznutritionalsolutions.com/     Instagram: https://www.instagram.com/doctorkiltz/      Tiktok: https://www.tiktok.com/@doctorkiltz    Facebook: https://www.facebook.com/doctorkiltz    Twitter: https://mobile.twitter.com/doctorkiltz    Amazon: https://www.amazon.com/Robert-Kiltz/e/B005EIXDWU%3Fref=dbs_a_mng_rwt_scns_share      Books by Dr. Kiltz: https://www.doctorkiltz.com/books-by-dr-kiltz/

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours Today on the podcast, Mikki speaks to Kristi Storoschuk, a passionate researcher, science communicator, and PhD candidate at Queen's University. Kristi's research focuses on exercise physiology, metabolic health, and the fascinating world of nutrient-exercise timing.In this episode, we dive into topics like mitochondrial biogenesis, behind fasted versus fed training, and Kristi's broader research interests in improving metabolic health and blood sugar regulation. Kristi also shares her insights on the practical applications of her work, touching on how science can inform our day-to-day choices in nutrition and exercise.Whether you're an athlete, a coach, or simply interested in optimising your health, this conversation is packed with actionable advice and thought-provoking science. Kristi Storoschuk is a researcher, science communicator, and PhD candidate in the Muscle Physiology Lab at Queen's University in Kingston, Ontario. Her academic work focuses on exercise physiology, metabolic health, and nutrient-exercise timing, with a particular interest in how these factors influence mitochondrial biogenesis and blood sugar regulation.Kristi's passion for health and nutrition stems from her early experiences working in her family's health food store. This foundation inspired her journey into research, where she bridges cutting-edge science with practical strategies to improve metabolic health and promote healthy aging.In addition to her academic pursuits, Kristi has over three years of experience writing on topics such as ketogenic diets, fasting, and metabolic therapies. She has contributed to platforms like Paleo Magazine, CrossFit, and the Zero Longevity app, and serves on the Scientific Advisory Board at Keto Kind. She is also a sought-after speaker and science communicator, known for her ability to make complex topics accessible and engaging. Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

Send us a textIn this episode of Causes or Cures, Dr. Eeks sits down with Dr. Alan Lightman to explore "spiritual materialism," the idea that we can embrace awe-inspiring, spiritual moments without turning to the supernatural for explanations. Dr. Lightman shares insights from his new book, The Miraculous From the Material: Understanding the Wonders of Nature, and delves into profound topics like consciousness, near-death experiences, the possibility of a higher power, immortality, relationships, and whether falling in love leaves space for magic. If you love pondering life's biggest questions, this episode is a must-listen.Dr. Lightman is a renowned physicist, author, and entrepreneur. A former Harvard faculty member and current professor at MIT, he holds a degree from Princeton University and a PhD in physics from Caltech. He's the bestselling author of the modern classic Einstein's Dreams, The Diagnosis, The Transcendental Brain, and The Accidental Universe. Dr. Lightman also hosts the acclaimed PBS series Searching: Our Quest for Meaning in the Age of Science. Since 2023, he is a member of the United Nations' Scientific Advisory Board.This episode is sponsored by Greco Gum, the all-natural chewing gum for your mouth and gut. Visit GrecoGum.com and use code ERIN15 to get 15% off your first order!*New* SUBSCRIBE for Causes or Cures+ Bonus Episodes & Monthly Live Q&As!You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here. Support the show

Episode #244: This week on Balance Your Life podcast I am joined by Dr. Michael Biamonte. Dr. Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced, initially designed for aerospace purposes.  As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. On this episode we talk about nutrients in general that society is lacking as a whole, supplements we should be taking and ones to avoid. We also discuss what type of blood work, mineral tests, and lab work we should be having done, the truth about seed oils, what categories of testing we should be looking at, and so much more! Spread the love by sharing this podcast with your friends and family! Don't forget to subscribe to the channel so you never miss an episode, and I would love if you took a moment to rate and review the show! ------------------------------------- Connect with Meghan: Instagram | TikTok | YouTube | Website Connect with Dr. Biamonte: Website | Book To Email the Show: info@balancebymeghan.com -------------------------------- Download the Holiday Gift Guide and Wellness Wishlist 2024 here ------------------------- Shop my Amazon Store Front where I link all my favourite wellness, lifestyle, pregnancy, and beauty products and brands.  ------------------------------------------  Join me by practicing yoga and fitness in the comfort of your home! Click here for my YouTube channel.  ------------------------------------------                                Access the Yoga Mama Journey: Journey to a Happy and Healthy Pregnancy and Baby Program and Guide here.

Dr. Olivardia is a clinical psychologist, lecturer in the Department of Psychiatry at Harvard Medical School and Clinical Associate at McLean Hospital. He maintains a private practice in Lexington, MA, where he specializes in the treatment of ADHD, executive functioning issues, and issues that face students with learning differences. He is a recognized expert in the treatment of body dysmorphic disorder (BDD), eating disorders and obsessive-compulsive disorder (OCD). He is on the Professional Advisory Boards for Children and Adults with ADHD (CHADD) and The Attention Deficit Disorder Association (ADDA), as well as sits on the Scientific Advisory Board for ADDitude and the Expert Network for Understood. He is co-author of The Adonis Complex, a book which details the various manifestations of body image problems in males. He has appeared in publications such as Time, GQ, and Rolling Stone, and has been featured on Good Morning America, Extra, CBS This Morning, CNN, and VH1. He has spoken on numerous radio and webinar shows and presents at many talks and conferences around the country. He also has lived experience as someone with ADHD and learning differences and a parent of two teenagers with ADHD and Dyslexia. Key Takeaways: 1. ADHD and Eating Disorders: ADHD impacts all life domains, with symptoms like impulsivity, executive dysfunction, and high sensory needs that influence eating behaviors. For many with ADHD, eating is driven by sensory-seeking, and the brain's need for stimulation can lead to unhealthy eating patterns. ADHD is often associated with binge eating and food impulsivity, influenced by genetic and neurological factors, such as dopamine dysregulation and low levels of GABA, the neurotransmitter related to inhibition.   2. Genetics, Food Culture, and Neurobiology: Dr. Olivardia shares how his family's love for food shaped his relationship with eating and sensory stimulation. ADHD brains often experience high stimulation from ultra-processed foods, which can drive cravings and overeating due to dopamine's role in the brain's reward system.   3. Executive Function Challenges in Meal Planning: ADHD can make meal planning, shopping, and cooking overwhelming. Structured lists, simple recipes, and single-pot meals can help manage mealtime more effectively for those with ADHD. Regular, scheduled meals prevent intense late-night eating often seen in ADHD.   4. Medication and Treatment Options: Stimulant medications, like Vyvanse (FDA-approved for binge eating disorder), help some individuals with ADHD manage impulsivity around food by improving focus and reducing cravings. Proper medication can significantly enhance treatment outcomes for ADHD-related eating challenges. For individuals who don't respond to medication, behavioral strategies such as maintaining regular sleep schedules, exercising, and using music for grounding can be effective.   5. Binge Eating and Addiction Risks:  Dr. Olivardia highlights the link between ADHD and addiction, including food addiction. ADHD brains metabolize glucose differently, leading to cravings for high-sugar foods. Education on how ADHD brains work can alleviate feelings of weakness or shame in managing eating behaviors.   6. Self-Acceptance and Neurodiversity: Dr. Olivardia encourages embracing ADHD and neurodiversity, emphasizing that people with ADHD often excel in creative and mission-driven fields. ADHD challenges can become strengths, leading to fulfilling, meaningful work and connections.   Resources: • CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) – A leading organization for ADHD support and resources: https://chadd.org   • Attitude Magazine – A resource for ADHD insights and content: https://www.additudemag.com   The content of our show is educational only. It does not supplement or supersede your healthcare provider's professional relationship and direction. Always seek the advice of your physician or other qualified mental health providers with any questions you may have regarding a medical condition, substance use disorder, or mental health concern.    

In this episode of the Bendy Bodies podcast, Dr. Linda Bluestein, the Hypermobility MD, has an in-depth conversation with Dr. Clair Francomano, a leading expert on connective tissue disorders and Chair of the Medical and Scientific Advisory Board for the Ehlers-Danlos Society. Dr. Francomano shares her insights on diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) versus hypermobility spectrum disorders (HSD), the current state of genetic testing, and emerging biomarkers (are we close?) that could revolutionize hEDS diagnosis. She discusses the potential connections between EDS, mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS), offering advice for patients navigating this complex landscape. With updates from ongoing research, this episode is essential listening for those with EDS or related conditions. Takeaways: Differences Between hEDS and HSD: Dr. Francomano explains the nuanced distinctions between hypermobile EDS (hEDS) and hypermobility spectrum disorders (HSD), noting that these categories may overlap more than previously thought and might benefit from unified diagnostic criteria in the future. Genetic Testing Red Flags: While genetic testing can be useful, Dr. Francomano highlights specific “red flags” in family history or personal health that should prompt a referral to a geneticist for further investigation. Current Limitations of Genetic Testing for hEDS: Unlike other types of EDS, hEDS currently has no identified genetic markers, meaning diagnosis relies on clinical criteria rather than genetic testing alone. Emerging Biomarkers Show Promise: New studies, such as those exploring fibronectin and calocrine, suggest potential biomarkers for hEDS and HSD, which could transform diagnosis and treatment in the future. Holistic Approach to Comorbidities: Dr. Francomano discusses how hEDS often presents with comorbidities like POTS and mast cell activation syndrome, recommending a comprehensive, multidisciplinary approach to manage these interconnected symptoms effectively. Connect with YOUR Bendy Specialist, Dr. Linda Bluestein, MD at https://www.hypermobilitymd.com/. Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/. Learn more about Human Content at http://www.human-content.com Podcast Advertising/Business Inquiries: sales@human-content.com YOUR bendy body is our highest priority! Learn about Dr. Clair Francomano Her Book: https://amzn.to/4e3eSaF Instagram: @dr.clairfrancomano Youtube: @DoctorClair Keep up to date with the HypermobilityMD: YouTube: youtube.com/@bendybodiespodcast Twitter: twitter.com/BluesteinLinda LinkedIn: linkedin.com/in/hypermobilitymd Facebook: facebook.com/BendyBodiesPodcast Blog: hypermobilitymd.com/blog Part of the Human Content Podcast Network Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Integrative Cancer Solutions, we are joined by Professor Dr. Sarper Diler, a distinguished medical doctor and oncologist, to discuss his unique approach to cancer treatment through integrative oncology. Prof. Diler shares his personal cancer journey, highlighting his battle with a large kidney tumor, treated through a combination of traditional surgery and alternative methods, including radical nephrectomy and the Gonzalez protocol.Key Discussion Points:Personalized Cancer Treatment: Prof. Diler emphasizes the importance of tailoring treatments to the individual, including the integration of pancreatic enzymes, specific diets, and detoxification. He shares insights into the Gonzalez protocol, which combines these elements to help support the body's natural healing processes.The Role of Pancreatic Enzymes: Drawing on historical and modern applications, Prof. Diler explains how pancreatic enzymes are used in cancer treatment and their significance in improving patient outcomes.Prof. Diler's Cancer Journey: From the moment he was diagnosed with a kidney tumor, Prof. Diler's experience shaped his transition from conventional oncology to integrative methods. His personal treatment approach, involving both surgery and alternative therapies, demonstrates the power of holistic cancer care.Belief and Compliance: One of the key takeaways from Prof. Diler's experience is the critical role of patient belief and adherence to the treatment protocol. He stresses that success with the Gonzalez protocol requires full commitment and belief in the process.Advancements in Cancer Treatment: Prof. Diler also touches on emerging technologies in cancer care, such as the potential for using wearable devices to deliver pancreatic enzymes, a field being researched at the Orbital Institute.Success Stories: Prof. Diler shares powerful testimonials of patients who have followed the Gonzalez protocol and experienced improved energy, mood, and quality of life.Action Items:Explore the Gonzalez Protocol website to learn more about integrative cancer treatments.Explore the Ovital Institute to learn moreConclusion:Dr. Diller's insights into integrative oncology offer hope and valuable knowledge for cancer patients and their families. Tune in to learn more about how personalized treatments can improve both quality of life and health outcomes.Be sure to visit the Karlfeldt Center website for more resources and information on future consultations.About Prof. Sarper Diler:He is the director of OVITAL Institute and serves as the Chair of the Scientific Advisory Board for the Nicholas Gonzalez Foundation in the US. He is highly active in numerous international scientific and patient-focused groups and committees.His previous roles include serving as the President of Myeloma Patients Europe (MPE), as a member of the European Cancer Organization Patient Advisory Committee (ECCO-PAC), the European Cancer Concord (ECC), and as Secretary General and Board Member of the Lymphoma Association (LC).Prof. Diler is a certified International Stem Cell Transplant Coordinator (CHTC) at the American National Donor Program (NMDP) and a specialist in Cancer Diet, Microbiome, and Heart Rate Variability, with certifications from Colorado Boulder and Arizona Universities, respectively. As an Integrative Oncologist, he holds memberships with SIO and BSIO. Additionally, he is a certified homeopath through the European Committee for Homeopathy (ECH) and the London College of Homeopathy (LCH).He has authored over 200 scientific articles and currently offers unique services worldwide under the umbrella of OVITAL Institute and OVITAL International Consultancy. His work also includes running preclinical and clinical trials focused on Cancer, Autonomic Nervous System clinical interferences, Epigenetics, Gut-Heart-Brain axis coherence, and Quantum diagnostics and treatments.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 ----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

In this episode, we're thrilled to welcome a very special guest, Lanning Ardente, the Co-Founder and CEO of Sorette—the new gold standard for motherhood products. Sorette not only offers a one-stop shop for safe and trusted products but also features their renowned Seal of Approval, developed by a team of leading toxicologists, thought partners, and their Scientific Advisory Board made up of OBGYNs, Dermatologists, Epidemiologists, Nutritionists, and experts in Women's Health.Lanning shares her journey from being a mom to creating Sorette, what inspired her to start this revolutionary brand, and how they developed their high standards to ensure that moms and families are surrounded by trusted products. Their approach allows moms to focus less on scrutinizing ingredient labels and more on what really matters—bonding with baby and taking care of themselves during this precious, transitional time.Shop now at https://shopsorette.com⭐️ Sorette has given our listeners an exclusive discount code. Use code: MOMCHAT15 to get 15% off your order.Make sure to also follow Sorette on Instagram: @shopsoretteJoin the official Mom Group Chat Facebook group: Mom Group Chat | FacebookKeep up with the Moms and join the conversation on our socials:Instagram: @‌momgroupchatTikTok: @‌momgroupchatQuestions/comments/need to vent? Email us at momgroupchat@gmail.com

Today on American Glutton Ethan welcomes Dr. Biamonte, author of The Candida Chronicles. Dr. Biamonte is a NY State certified Clinical Nutritionist, a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition, and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. SHOW HIGHLIGHTS(00:00) Episode Intro(00:38) Understanding Candida Overgrowth and Treatment(15:38) Navigating Personalized Supplement Recommendations(22:19) Exploring Metabolism, Candida, and Seed Oils(32:23) The Dangers of Polyunsaturated Oils(44:29) GMO Foods and Thyroid Dangers(54:14) Biochemical Individuality and Personalized Nutrition Hosted on Acast. See acast.com/privacy for more information.

In this video, Riley interviews Jini Glaros, the Chief Science Officer (CSO) at Modern Canna, about groundbreaking research on the relationship between water activity and moisture content in cannabis. Whether you're part of an MSO, a home grower, or just passionate about cannabis science, understanding how these factors influence product quality, shelf life, and data accuracy is essential. Watch as Jini shares key insights from her experiments and discusses how this information can help improve industry standards and reporting practices. Don't miss out on these valuable takeaways that can elevate your knowledge and practices in cannabis cultivation and quality control.

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system.   ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠   https://braingym.fitness/⁠    ------------    Speaking Podcast Social Media / Coaching My Other Podcasts    ⁠⁠⁠https://roycoughlan.com/⁠⁠   Find the Products mentioned in this Episode or Join the Business   https://partnerco.world/ ------------------    About my Guest Dr Kristal Vance:   Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council.   What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins)   - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins)   - The Industry is Broken (8 mins)   - The 2 Founders of Partner Co (9 mins to18:55mins)   - Tahetian Noni Jucie (11 mins)   - The got 14 legacy Companies (16:30 mins)   - The have a Scientific Advisory Board (17:20 mins)   - Why this Noni is so beneficial (19:40 mins)   - How the Drops helped her Father David Vance (21 mins)   - The Dangers of Sugar (23:15 mins)- I lost me (24 mins)   - Why Dieting did not seem right (25:30 mins)   - 6 yrs out and she kept the Weight off (27:30 mins)   - Mom was on 19 Medications and now just 4 (27:45 mins)   - They created a Community for Health support (29:50 mins)   - My Food Ant Test (31:30 mins)   - If only our Bodies had a Low Battery display (33 mins)   - Over 100 Products that have has proper testing(34:30 mins)    - Low Entry Point to the Business $29.95 (36 mins)     Find the Products or Start in the Business :    https://partnerco.world/  ------------------------------   Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors    http://meditationpodcast.org/   Our Facebook Group can be found at ⁠   https://www.facebook.com/meditationpodcast.org

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system.   ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠   https://braingym.fitness/⁠    ------------    Speaking Podcast Social Media / Coaching My Other Podcasts    ⁠⁠⁠https://roycoughlan.com/⁠⁠   Find the Products mentioned in this Episode or Join the Business   https://partnerco.world/ My Website https://partner.co/?custid=N6543249 ------------------    About my Guest Dr Kristal Vance:   Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council.   What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins)   - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins)   - The Industry is Broken (8 mins)   - The 2 Founders of Partner Co (9 mins to18:55mins)   - Tahetian Noni Jucie (11 mins)   - The got 14 legacy Companies (16:30 mins)   - The have a Scientific Advisory Board (17:20 mins)   - Why this Noni is so beneficial (19:40 mins)   - How the Drops helped her Father David Vance (21 mins)   - The Dangers of Sugar (23:15 mins)- I lost me (24 mins)   - Why Dieting did not seem right (25:30 mins)   - 6 yrs out and she kept the Weight off (27:30 mins)   - Mom was on 19 Medications and now just 4 (27:45 mins)   - They created a Community for Health support (29:50 mins)   - My Food Ant Test (31:30 mins)   - If only our Bodies had a Low Battery display (33 mins)   - Over 100 Products that have has proper testing(34:30 mins)    - Low Entry Point to the Business $29.95 (36 mins)     Find the Products or Start in the Business :    https://partnerco.world/ My Website https://partner.co/?custid=N6543249  ------------------------------   Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors    https://www.awakeningpodcast.org/   Our Facebook Group can be found at ⁠   https://www.facebook.com/royawakening

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system.   ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠   https://braingym.fitness/⁠    ------------    Speaking Podcast Social Media / Coaching My Other Podcasts    ⁠⁠⁠https://roycoughlan.com/⁠⁠   Find the Products mentioned in this Episode or Join the Business   https://partnerco.world/ ------------------    About my Guest Dr Kristal Vance:   Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council.   What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins)   - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins)   - The Industry is Broken (8 mins)   - The 2 Founders of Partner Co (9 mins to18:55mins)   - Tahetian Noni Jucie (11 mins)   - The got 14 legacy Companies (16:30 mins)   - The have a Scientific Advisory Board (17:20 mins)   - Why this Noni is so beneficial (19:40 mins)   - How the Drops helped her Father David Vance (21 mins)   - The Dangers of Sugar (23:15 mins)- I lost me (24 mins)   - Why Dieting did not seem right (25:30 mins)   - 6 yrs out and she kept the Weight off (27:30 mins)   - Mom was on 19 Medications and now just 4 (27:45 mins)   - They created a Community for Health support (29:50 mins)   - My Food Ant Test (31:30 mins)   - If only our Bodies had a Low Battery display (33 mins)   - Over 100 Products that have has proper testing(34:30 mins)    - Low Entry Point to the Business $29.95 (36 mins)     Find the Products or Start in the Business :    https://partnerco.world/  ------------------------------   Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors    https://www.awakeningpodcast.org/   Our Facebook Group can be found at ⁠   https://www.facebook.com/royawakening

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠ https://braingym.fitness/⁠  ------------  Speaking Podcast Social Media / Coaching My Other Podcasts  ⁠⁠⁠https://roycoughlan.com/⁠⁠ Find the Products mentioned in this Episode or Join the Business https://partnerco.world/ ------------------  About my Guest Dr Kristal Vance: Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council. What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins) - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins) - The Industry is Broken (8 mins) - The 2 Founders of Partner Co (9 mins to18:55mins) - Tahetian Noni Jucie (11 mins) - The got 14 legacy Companies (16:30 mins) - The have a Scientific Advisory Board (17:20 mins) - Why this Noni is so beneficial (19:40 mins) - How the Drops helped her Father David Vance (21 mins) - The Dangers of Sugar (23:15 mins)- I lost me (24 mins) - Why Dieting did not seem right (25:30 mins) - 6 yrs out and she kept the Weight off (27:30 mins) - Mom was on 19 Medications and now just 4 (27:45 mins) - They created a Community for Health support (29:50 mins) - My Food Ant Test (31:30 mins) - If only our Bodies had a Low Battery display (33 mins) - Over 100 Products that have has proper testing(34:30 mins)  - Low Entry Point to the Business $29.95 (36 mins) Find the Products or Start in the Business :  https://partnerco.world/  ------------------------------ Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors  ⁠https://www.speakingpodcast.com/⁠   Our Facebook Group can be found at ⁠ https://www.facebook.com/speakingpodcast⁠

In episode 167, I discuss candida infections with Dr. Michael Biamonte. Topics covered in this episode include: What is candida? What allows candida to be overgrown? The challenges caused by candida overgrowth Foods that aggravate candida-related symptoms The connection between thyroid conditions and candida And more... Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes. As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living. He holds a Doctorate of Nutripathy and is a certified clinical nutritionist in New York State. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. Facebook - https://www.facebook.com/The-Biamonte-Center-241435772676317/ YouTube - https://www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ www.health-truth.com

In this episode, I speak with Dr. Bill Campbell, a member of our Scientific Advisory Board. We explore the critical importance of whole food nutrition for fat loss and emphasize the vital role of protein in your diet.     We explain the significant differences between processed and whole foods, and discuss how making healthier food choices can dramatically improve your body composition, metabolism, and energy levels. We share eye-opening studies and practical tips to help you follow a whole food-based meal plan.   Dr. Campbell and I also highlight the necessity of protein for muscle building, while providing practical advice on daily protein intake and its distribution throughout the day. We also discuss the benefits of high-quality protein sources, both animal-based and plant-based, and how a higher protein diet can support your fat loss goals by increasing satiety. Our conversation is packed with actionable insights that can help you optimize your nutrition. Sign up for the Summer Slimdown: https://summerslimdown.fasterwaytofatloss.com/   Don't forget to check out our merch, supplements and other great deals: https://fasterwayshop.com/   Subscribe: youtube.com/FASTerWaytoFatLoss   Follow us on Instagram: Amanda Tress: https://www.instagram.com/amandatress FASTer Way to Fat Loss: https://www.instagram.com/fasterwaytofatloss Dr. Bill Campbell: https://www.instagram.com/billcampbellphd/  

In this episode of Exploring the Marketplace, Shawn Bolz and Bob Hasson sit down with Dr. Lee Cowden. W. Lee Cowden, MD, MD(H), is Chairman of the Scientific Advisory Board & Professor of the Academy of Comprehensive Integrative Medicine. He has been a USA board-certified cardiologist & internist and a licensed homeopathic medical doctor, but recently retired from patient care & is now teaching full-time. He has been studying integrative medicine since he was at the University of Texas Medical School at Houston in 1975-78. He has co-authored 6 books & is internationally known for his knowledge and skill in practicing & teaching integrative medicine. He has pioneered successful treatments for cancer, Lyme disease, atherosclerosis, cardiomyopathy, various neurological conditions, silicone implant disease and other illnesses, but he gives credit to God, Jesus and the Holy Spirit as the ultimate source of all healing. In this episode, Dr Lee Cowden discusses pressing topics such as job loss, layoffs, and finding encouragement through faith during challenging times. Dr. Cowden shares his insights and powerful words of knowledge he received that have empowered individuals to overcome seemingly impossible health conditions. Join us as we delve into Dr. Cowden's unique perspective and explore how faith can provide strength and resilience in the face of adversity. Discover powerful strategies for navigating uncertainty and finding hope in the midst of life's storms.Come join me on my Social Media: Facebook: ShawnbolzTwitter: ShawnBolzInstagram: ShawnBolzTikTok: ShawnBolzYouTube: ShawnBolzofficialTake a class or attend an event at our Spiritual Growth Academy: Our 4 week classes and monthly events are designed to do the heavy lifting in your spiritual growth journey. Learn how to hear from God, stay spiritually healthy, and impact the world around you: https://bit.ly/3B2luDRTake a read: Translating God - Hearing God's voice for yourself and the world around you https://bit.ly/3RU2X3FEncounter - A spiritual encounter that will shape your faith https://bit.ly/3tNAW4YThrough the Eyes of Love - http://bit.ly/2pitHTbWired to Hear - Hearing God's voice for your place of career and influence https://bit.ly/3kLsMn9Growing Up With God - Chapter book and kids curriculum https://bit.ly/3eDRF5aKeys to Heaven's Economy - Understanding the resources for your destiny: https://bit.ly/3TZAc7uEmail My Assistant: assistant@bolzministries.comOur resources: resources@bolzministries.comOur office: info@bolzministries.com

Welcome to Protecting Your Nest with Dr. Tony Hampton. Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced. He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans” for his research in Nutrition and Physiology. In this discussion, Drs. Tony and Michael talk about: (02:32) Why Dr. Michael chose to focus on nutrition and supplementation (05:55) The future of genetic and functional testing in patient care (09:13) How functional testing for nutritional deficiencies in a given person works (15:50) How the average person can know if they are taking the right supplements and how your hair might hold the key to answering this question (27:30) Tips for people seeking to heal from Candida and Hashimoto's (33:07) Dietary treatments for Candida (34:17) How blood type plays a role in choosing the right diet for you (39:36) Why people should not be too cavalier when it comes to taking vitamin supplements (43:25) How medications can lead to deficiencies in the body and make us sick (45:03) Problems with most vitamin supplements sold on the market (49:07) How supplements, medications, and diet impact the microbiome and how the microbiome then impacts the body (52:52) How Dr. Michael's approach is different from a more standard Western doctor (54:20) The importance of eating organic and non-GMO foods (54:56) How to find a good doctor who can test you accurately for nutritional deficiencies Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.   Links:   Dr. Michael Biamonte: The Biamonte Center for Clinical Nutrition New Your City Candida Doctor New Your City Thyroid Doctor   Dr. Tony Hampton: Linktree Instagram Account LinkedIn Account Ritmos Negros Podcast Q Med Symposium for Metabolic Health Lectures How Waking Up Every Day at 4:30 Can Change Your Life

Drew Ramsey, MD @DrewRamseyMD is a board certified psychiatrist, author, and mental health advocate. His work focuses on clinical excellence, nutritional psychiatry, male mental health and creative media. He is an assistant clinical professor of psychiatry at Columbia University College of Physicians and Surgeons and founded the Brain Food Clinic, a digital mental health clinical practice. His work has been featured by The New York Times, The Wall Street Journal, Lancet Psychiatry, The Today Show, BBC, and NPR and he has given three TEDx talks. He is co-author of the Antidepressant Food Scale and created the first e-courses on Nutritional Psychiatry education for the public and clinicians. His books Eat to Beat Depression and Anxiety (Harperwave 2021), Eat Complete, 50 Shades of Kale, and The Happiness Diet explore the connections between mental health and nutrition. He is on the Advisory Board at Men's Health, the Editorial Board at Medscape Psychiatry, and the Scientific Advisory Board of the anti-stigma nonprofit Bring Change To Mind. He lives in Jackson, Wyoming with his wife and two children. In today's episode, Dr. Ramsey and I discuss how food can contribute to our mood. He emphasizes the importance of nourishing the brain with the right foods to optimize mental health and potentially prevent and treat mental health concerns. Dr. Ramsey also highlights the significance of educating ourselves about the nutrients our brains need, such as magnesium, vitamin E, and omega-3 fats, and where to find them in our diets. In addition to food, we touched on the topic of alternative treatments for mental health, particularly ketamine. Dr. Ramsey explained ketamine's history, its use in treating depression, and its potential to open up neuroplastic windows in the brain, offering new pathways for healing. This episode is a must-listen for anyone interested in the powerful connection between what we eat and how we feel. Dr. Ramsey's expertise and passion for nutritional psychiatry is truly inspiring, and his insights could be the key to unlocking a happier, healthier life for you! Dr. Ramsey's Instagram: https://www.instagram.com/drewramseymd/ Dr. Ramsey's Youtube: https://www.youtube.com/@DrewRamseyMD/featured Dr. Ramsey's Latest Book: https://drewramseymd.com/books-publications/eat-to-beat-depression-and-anxiety/ Healing the Modern Brain course: https://learn.drewramseymd.com/masterclass-order-evergreen/ For $250 off your Lumebox, preorder for their updated model launching this January 2024, using this link: https://justingredients.us/products/lumebox-red-light?_pos=1&_sid=e88ca0cba&_ss=r